 
 Clinical Trial Protocol : THR-1442 -C-480 
Study Title:  A Phase 3, Randomized, Double -Blind, Active -Controlled Study to 
Evaluate the Effects of Bexagliflozin versus Glimepi[INVESTIGATOR_532483] 2 Diabetes Mellitus Who Ha ve Inadequate Glycemic 
Control by [CONTACT_532575]:  THR -1442 -C-480 
Study Phase:  [ADDRESS_691421] Name:  [CONTACT_272341]:  Type 2 Diabetes Mellitus  
Investigators:  Multicenter  study  
EudraCT Number:  2016 -002013 -21 
IND Number:  103822  
Spon sor: Theracos Sub, LLC  
Sponsor Contact:  [CONTACT_532576], Ph.D.  
Project Manager  
Translational Medicine Group  
[LOCATION_005] General Hospi[INVESTIGATOR_307]  
[ADDRESS_691422], [LOCATION_011], MA [ZIP_CODE]  
Phone: 1 -[PHONE_11031]  
Fax:  617 -643-8203  
E-mail: [EMAIL_10178]   
Medi cal Monitor:  J. Paul Lock, M.D.  
Theracos Sub, LLC  
[ADDRESS_691423], Marlborough, MA [ZIP_CODE]  
Phone: 1 -[PHONE_5670]  
Fax: 617 -643-8203  
E-mail: [EMAIL_5284]  
 
 Date  
Version 3.0: 27 October 2016  
 
Confidentiality Statement  
The information in  this document is the confidential information of Theracos Sub, LLC 
(“Theracos”) and must not be disclosed, used, or copi[INVESTIGATOR_272190], rules and regulations . 
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 2 of 79 Version 3.0  (Global ) TABLE OF CON TENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ .[ADDRESS_691424] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .......... 13 
1 INTRODU CTION  ................................ ................................ ................................ ........... 16 
1.1 Type 2 Diabetes Mellitus  ................................ ................................ ....................... 16 
1.2 Bexagliflozin for the Treatment of Type 2 Diabetes Mellitus  ............................... 17 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....18 
2.1 Primary Objective  ................................ ................................ ................................ ..18 
2.2 Key Secondary Objectives  ................................ ................................ ..................... 18 
2.3 Exploratory Objectives  ................................ ................................ .......................... 18 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 20 
3.1 Overall Study Des ign and Plan  ................................ ................................ .............. 20 
3.2 Rationale for Study Design and Control Group  ................................ ..................... 20 
3.2.1  Rationale for Background Medication and Active Comparato r .................. 20 
3.2.2  Rationale for the Study Design  ................................ ................................ ....21 
3.2.3  Rationale for the Dose Selection ................................ ................................ ..21 
3.3 Research Methods and Procedures  ................................ ................................ ........ 22 
3.3.1  Wash -out and Run -in Period  ................................ ................................ ........ 22 
3.3.2  Treatment Period  ................................ ................................ .......................... 23 
[IP_ADDRESS]  Glimepi[INVESTIGATOR_532484]  ................................ ................................ 24 
3.3.3  Glycemic Control Monitoring ................................ ................................ ......26 
[IP_ADDRESS]  Wash -out Period and Placebo Run -in Period ................................ .....26 
[IP_ADDRESS]  Treatment Period  ................................ ................................ ................ 26 
[IP_ADDRESS]  Intensification of Medical Therapy for Hyp erglycemia  .................... [ADDRESS_691425] (DSMB)  ................................ ............... 28 
3.3.6  Major Adverse Cardiovascular Event (MACE) Adjudication  ..................... 29 
3.3.7  Diabetic Ketoacidosis (DKA) Event Adjudication  ................................ ......[ADDRESS_691426]  ................................ ................................ ................ 32 
5.1.2  Active Comparator  ................................ ................................ ....................... 32 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 3 of 79 Version 3.0  (Global ) 5.[ADDRESS_691427] Retention at Study Site  ................................ .................... 38 
6 STUDY PROCEDURES  ................................ ................................ ................................ .39 
6.1 Informed Consent ................................ ................................ ................................ ...39 
6.2 Screening for I/E Criteria  ................................ ................................ ....................... 39 
6.3 Medical History  ................................ ................................ ................................ .....39 
6.3.1  General Demographics and Characteristics  ................................ ................. 39 
6.3.2  Diabetes History ................................ ................................ ........................... 39 
6.3.3  Cardiovascular Disease History  ................................ ................................ ...40 
6.3.4  Medication History  ................................ ................................ ...................... 40 
6.4 Diet and Exercise Counseling  ................................ ................................ ................ 40 
6.5 Physical Examination ................................ ................................ ............................. 40 
6.6 Abbreviated Physical Examination  ................................ ................................ ........ 40 
6.7 Vital Signs  ................................ ................................ ................................ .............. 41 
6.8 Electrocardiography  ................................ ................................ ............................... 41 
6.9 Clinical Laboratory Tests  ................................ ................................ ....................... 42 
6.9.1  Laboratory Parameters  ................................ ................................ ................. 42 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 4 of 79 Version 3.0  (Global ) 6.9.2  Sample Collection, Storage, and Shippi[INVESTIGATOR_007]  ................................ .................. 42 
[IP_ADDRESS]  Hematology, Blood Chemistry, Serum Lipi[INVESTIGATOR_805], and Glycemic 
Control Assessments  ................................ ................................ .......... 42 
[IP_ADDRESS]  Urinalysis  ................................ ................................ ........................... 42 
[IP_ADDRESS]  Urine Pregnancy Test (UPT)  ................................ ............................. [ADDRESS_691428] Infections (UTIs)  ................................ ................................ ...50 
6.14.9  Genital Mycotic Infections (GMIs)  ................................ ............................. 51 
6.14.10  Hepatotoxicity  ................................ ................................ .............................. 51 
6.14.11  Hypoglycemia  ................................ ................................ .............................. 52 
6.14.12  Diabetic Ke toacidosis (DKA)  ................................ ................................ ......54 
6.14.13  Major Adverse Cardiovascular Event (MACE)  ................................ ........... [ADDRESS_691429] Administration  ................................ ................................ .......................... 56 
6.18  Appropriateness of Measurements  ................................ ................................ ......... 56 
7 STUDY ACTIVITIES  ................................ ................................ ................................ .....57 
7.1 Screening Period  ................................ ................................ ................................ ....57 
7.1.1  Visit V1 (3 days to 3 weeks for metformin -only group and up to 9 
weeks f or metformin -and-OHA group before run -in period)  ...................... 57 
7.2 Wash -out and Run -in Period (Up to 8 weeks prior to randomization)  .................. 57 
7.2.1  Wash -out Period (Visits V2 and V3)  ................................ ........................... 57 
[IP_ADDRESS]  Visit V2 (8 weeks prior to randomization)  ................................ ........ 58 
[IP_ADDRESS]  Visit V3 (6 weeks prior to ran domization, off -site phone visit)  ........ 58 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 5 of 79 Version 3.0  (Global ) 7.2.2  Run-in Period  ................................ ................................ ............................... 58 
[IP_ADDRESS]  Visit V4 (2 weeks prior to randomization)  ................................ ........ 58 
[IP_ADDRESS]  Visit V5 (3 to 5 days prior to randomization)  ................................ ....58 
7.3 Treatment Period (Day 1 to Week 96)  ................................ ................................ ...59 
7.3.1  Visit V6 (Day 1 of Week 1)  ................................ ................................ ......... 59 
7.3.2  Visit V 7 (Week 2)  ................................ ................................ ........................ 59 
7.3.3  Visit V 8 (Week 4)  ................................ ................................ ........................ 59 
7.3.4  Visit V 9 (Week 6)  ................................ ................................ ........................ 59 
7.3.5  Visit V 10 (Week 12)  ................................ ................................ .................... 60 
7.3.6  Visit V 11 (Week 24)  ................................ ................................ .................... 60 
7.3.7  Visit V 12 (Week 36)  ................................ ................................ .................... 60 
7.3.8  Visit V 13 (Week 48) ................................ ................................ .................... 61 
7.3.9  Visit V14  (week 60)  ................................ ................................ ..................... 61 
7.3.10  Visit V15 (week 72)  ................................ ................................ ..................... 61 
7.3.11  Visit V16 (week 84, off -site phone visit) ................................ ..................... 61 
7.3.12  Visit V17 (end of treatment, week 96)  ................................ ......................... 62 
7.4 Visit V18 (Exit Visit or Early Termination Visit)  ................................ ................. 62 
7.4.1  Visit V18 (week [ADDRESS_691430] withdraws consent)  ......................... [ADDRESS_691431] Adm inistration  ................................ ..62 
7.6 Early Termination Procedures  ................................ ................................ ............... 62 
8 QUALITY CONTROL AND ASSURANCE  ................................ ................................ .64 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 65 
9.1 General Considerations  ................................ ................................ .......................... 65 
9.2 Determination of Sample Size  ................................ ................................ ............... 65 
9.3 Analysis Populations  ................................ ................................ .............................. 66 
9.3.1  Intention -to-Treat Analysis set  ................................ ................................ ....66 
9.3.2  Safety Analysis Set  ................................ ................................ ...................... 66 
9.3.3  Per Protocol Analysis Set ................................ ................................ ............. 66 
9.4 Demographics and Baseline Characteristics  ................................ .......................... 66 
9.4.1  Concomitant Medications  ................................ ................................ ............ 67 
9.5 Primary Efficacy Analyses  ................................ ................................ .................... 67 
9.5.1  Hypotheses for the Pri mary Endpoint  ................................ .......................... 67 
9.5.2  Statistical Methods for Primary Analyses ................................ .................... 67 
9.5.3  Analysis of Dropouts Pattern  ................................ ................................ .......68 
9.6 Secondary Efficacy Analyses  ................................ ................................ ................ 68 
9.7 Other Efficacy Analyses  ................................ ................................ ........................ 69 
9.8 Analysis of Safety  ................................ ................................ ................................ ..69 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 6 of 79 Version 3.0  (Global ) 9.8.[ADDRESS_691432] (IRB) or Independent Ethics Committee (IEC) 
Approval  ................................ ................................ ................................ ................ [ADDRESS_691433] Confidentiality  ................................ ................................ .......................... 72 
10.6  Study Monitoring  ................................ ................................ ................................ ...72 
10.7  Case Report Forms and S tudy Records  ................................ ................................ .73 
10.8  Data Monitoring Committee  ................................ ................................ .................. 73 
10.9  Protocol Violations/Deviations  ................................ ................................ .............. [ADDRESS_691434] OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ............. 76 
Appendix 2  Schedule of Clinical Laboratory Tests  ................................ ............... 77 
Appendix 3  Sponsor Signatures ................................ ................................ ............. 78 
Appendix 4 Investigator’s Signature  ................................ ................................ .....79 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 7 of 79 Version 3.0  (Global ) SYNOPSIS  
Sponsor : 
Theracos Sub, LLC  
Name [CONTACT_2756]:  Bexagliflozin Tablets   
Name [CONTACT_3261]:  Bexagliflozin  
Study  Title : 
A Phase 3, Randomized, Double -Blind, Active -Controlled Study to Evaluate the Effects of 
Bexagliflozin versus Glimepi[INVESTIGATOR_532485] 2 Diabetes Mellitus Who Ha ve 
Inadequate Glycemic Control by [CONTACT_532577]:  THR -1442 -C-480 
Study Phase:  3 
Primary Objective:   
The primary efficacy objective  is to demonstrate that bexagliflozin is non -inferior to 
glimepi[INVESTIGATOR_532486] A1c ( HbA1c ) reduction  at 
week 60 in subjects whose type 2 diabetes mellitus  (T2DM)  is inadequately controlled by 
[CONTACT_14424].  
Secondary Objective s: 
The key secondary objectives are : 
• To evaluate the treatment effect of bexagliflozin  vs. glimepi[INVESTIGATOR_532487] ( BMI ) ≥ 25 kg/m2 at week 60  
• To evaluate the treatment effect of bexagliflozin  vs. glimepi[INVESTIGATOR_532488] (SBP) in subjects with baseline SBP ≥ 140 mmHg  at week 60  
• To evaluat e the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532489] ≥  1 severe or documented symptomatic hypoglycemia event s 
over 96 weeks  
• To evaluate if  bexagliflozin is superior to glimepi[INVESTIGATOR_532490]1c  reduction  at week 60  
Exploratory  Objectives :  
• To assess the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532491]1c < 7.0%  over time  
• To assess the  treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532492]1c 
over time  
• To evaluate the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532493]  (FPG) over time  
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532494] 
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532495]  
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532496]  ≥ 1 severe or documented symptom atic hypoglycemia event s 
over time  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 8 of 79 Version 3.0  (Global ) Safety Objectives:  
• To compare the effects of bexagliflozin vs. glimepi[INVESTIGATOR_532497]. Adverse events of interest are urinary tract infections including 
urosepsis and pyelonephritis, ge nital mycotic infections, diuretic effects including 
hypovolemia, hypotension epi[INVESTIGATOR_1841], hypoglycemia, hepatotoxicity, major adverse 
cardiovascular events (MACE), falls and fractures, malignancies, hypersensitivity 
reactions, acid -base disorders including d iabetic ketoacidosis, and renal failure events . 
• To compare the effects of bexagliflozin vs. glimepi[INVESTIGATOR_532498], clinical laboratory events, 12 -lead 
electrocardiograms (ECG) parameters, phys ical examinations, vital signs including 
orthostatic blood pressure, and use of concomitant medications  
Other Objectives:  
• To compare the effects of bexagliflozin vs glimepi[INVESTIGATOR_532499] -related quality of life 
using a validated instrument  EQ-5D-3L. 
Study  Design :  
THR -1442 -C-480 is a phase 3, multi -center, randomized, double -blind, parallel -group study 
to evaluate the efficacy and safety of bexagliflozin  versus glimepi[INVESTIGATOR_532500]  T2DM is 
inadequately controlled by [CONTACT_14424]. A  total of 420 subjects are planned to be randomized 
in a ratio of 1:1 to receive once daily treatment of active bexagliflozin with placebo 
glimepi[INVESTIGATOR_14956] (Group 1) or placebo bexagliflozin with active glimepi[INVESTIGATOR_14956] (Group 2) for 96 
weeks  in an outpatient setting. Active treatment in Gro up 1 will be bexagliflozin tablets, 
20 mg. Active treatment in Group 2 will be glimepi[INVESTIGATOR_532501], 2, 4, or 6 mg. At the time of 
screening , subjects will be taking metformin only (metformin -only) or metformin in addition 
to no more than one additional or al hypoglycemic agent (metformin -and-OHA). Study 
subjects  will continue receiving open -label ed metformin background medication  during the 
entire study.   
The m ain eligibility criteria include 1) male or female subjects with T2DM  and 2) screening 
HbA1c betwe en 7.0% and 10.5%  (inclusive)  for subjects who are metformin -only treated , or 
screening HbA1c between 6.5% and 10.0%  (inclusive)  for subjects who are metformin -and-
OHA treated . 
All eligible subjects must have taken metformin at a stable dose of  ≥ 1500  mg/day for at least  
[ADDRESS_691435] completed the 6-week wash -out 
period will start a 2 -week single -blind run -in period . During the run-in, subjects will receive 
placebo bexagliflozin and placebo glimepi[INVESTIGATOR_14956]. Subjects who meet all inclusion criteria and 
no exclusion criteria prior to randomization  will be eligible for randomization and receive 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 9 of 79 Version 3.0  (Global ) investigational product s.  
During the trea tment period, g limepi[INVESTIGATOR_532502] : 2 mg, 4 mg, 
and 6 mg . Placebo glimepi[INVESTIGATOR_532503]: placebo for 2 mg, 
placebo for 4 mg, and placebo for 6 mg . Subjects will receive the  starting dose of 
glimepi[INVESTIGATOR_14956],  2 mg  or placebo . Subjects who meet protocol -specified glycemic criteria will 
undergo up -titration of the glimepi[INVESTIGATOR_532504] 2, 4, and 6. The dose will be increased 
to the next dosing level if during the proceeding 2 weeks: (1) ≥ 50% of fasting  SMBG 
measurements ˃ 110 mg/dL  and (2) no severe or documented symptomatic  hypogly cemia 
events . Subjects assigned to receive placebo  glimepi[INVESTIGATOR_14956] , will receive mock titrations  of 
glimep iride at weeks 2, 4, and [ADDRESS_691436] will be instructed to return to the cl inic at weeks  0, 2, 4, 6, 12, 24, 36 , 48, 60, 
72, 84 (off-site phone visit)  and [ADDRESS_691437] (DSMB) will review the unblinded 
data pe riodically and may recommend an early termination of the trial for safety reasons. In 
the event of administrat ive changes  or other  related  reasons, the sponsor reserves the rights to 
terminate the study early. There will be no interim analysis ; final stati stical analysis will be 
performed after all subjects complete the study . 
Study Population  and Main Eligibility Criteria : 
A total of 420 eligible subjects  are planned for this study. The study population will 
comprise:  
1. Male or female adult subjects ≥ [ADDRESS_691438] and agree to abstain from coitus or use contraception during the entire 
study to avoid any possible pre gnancy  
3. Subjects who are in one of the two categories : 
a. Metformin -only treated: receive ≥ 1500 mg/day metformin  only for at least 8 weeks 
prior to screening  or  
b. Metformin -and-OHA treated: receive  ≥ 1500 mg/day metformin  for at least 8 weeks  
prior to screeni ng and ≥ 14 days of 1 additional oral hypoglycemia agent (OHA)  in 
the 8 weeks prior to screening .  
4. Subjects with a diagnosis of T2DM with HbA1c levels between 7.0% and 10.5% 
(inclusive) at screening if metformin -only treated or with HbA1c levels between 6. 5% 
and 10.0% (inclusive) at screening if metformin - and-OHA treated   
5. Subjects with a body mass index (BMI) ≤ 45 kg/m2 at screening  
6. If applicable, taking stable doses of treatment for dyslipi[INVESTIGATOR_83281]/or hypertension for 30 
days prior to screening. Subjects  do not need to be treated for dyslipi[INVESTIGATOR_532505], LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 10 of 79 Version 3.0  (Global ) 7. Subjects who are w illing and able to return for all clinic visits and to complete all study -
required procedures, including self -monitor ing blood glucose (SMBG) measure ment s 
 
Prior to randomization, all subjects must : 
8. Maintain adequate glycemic control during the washout and  run-in periods  (fasting 
plasma glucose values are not ≥ 250 mg/dL on consecutive days ) 
9. Have  an HbA1c between 7.0 % and 10.5% (in clusive) at Visit V5 
10. Adhere  to the investigational product administration requirements as evidenced by 
[CONTACT_532578] [ADDRESS_691439] Produ cts, Dose , and Mode of Administration:  
Once daily oral administration of bexagliflozin and glimepi[INVESTIGATOR_14956]  
• Group 1: bexagliflozin tablets , 20 mg, and glimepi[INVESTIGATOR_532501], placebo   
• Group 2:  bexaglifl ozin tablets , placebo, and  glimepi[INVESTIGATOR_532501] , 2 mg, 4 mg or 6 mg 
 
Duration of Treatment :  
Eligible subjects  will receive a total treatment duration of  [ADDRESS_691440] s. 
 
Efficacy  Assessments : 
Primary efficacy assessment : 
• Change in HbA1c fr om baseline  at week 60  
 
Secondary efficacy assessment s: 
• Change in body weight in subjects with baseline body mass index (BMI) ≥  25 kg/m2 at 
week 60  
• Change in SBP  in subjects with  baseline SBP ≥ 140 mmHg from baseline at week 60 
• Difference in p roportion of subjects with ≥ 1 severe or documented symptomatic  
hypoglycemia event s over 96 weeks  
• Change in HbA1c from baseline at week 60 
 
Other efficacy endpoints:  
• Change in p roportion of subjects achieving HbA1c < 7.0% over time  
• Change in body weight over time  
• Chang e in FPG over time  
• Change in SBP over time  
• Change in HbA1c over time  
• Difference in p roportion of subjects with ≥ 1 sever e or documented  symptomatic  
hypoglycemia event s over time  
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 11 of 79 Version 3.0  (Global ) Safety Endpoints:  
• Adverse events , including adverse events of special interes t (genital and urinary tract 
infections, diuretic effects, hepatotoxicity, MACE, hypoglycemia, fractures, malignancy, 
hypersensitivity reactions, hypotensive epi[INVESTIGATOR_1841], acid -base disorders, and renal failure 
events)  
• Laboratory testing , including hematology,  serum chemistry, and urinalysis  
• Physical examination  
• 12-lead ECG  
• Vital signs  
• Concomitant medication use  
 
Other Assessment : 
Health -related quality of life  instrument  EQ-5D-3L 
Statistical Methods:   
The primary hypothesis is that bexagliflozin is non -inferi or to glimepi[INVESTIGATOR_532506]1c reduction at week 60  in combination with metformin . The non -
inferiority margin for mean change from  baseline at week  60 in HbA1c comparing 
bexagliflozin group with glimepi[INVESTIGATOR_532507] 0.35 %. Superiority will be declared 
without additional statistical testing when the upper bound of the 95% CI for difference in 
change from baseline at week 60 in HbA1c comparing bexagliflozin group with glimepi[INVESTIGATOR_532508] 0. The treatment differen ce will be examined by [CONTACT_2329] a mixed model 
repeated measures (MMRM) analysis of covariance model (ANCOVA). The model will 
include  treatment, visit, treatment -by-visit interaction and randomization stratification factors 
as the fixed effects terms and the b aseline HbA1c value as a fixed effect covariate. Least 
squares mean treatment differences between the bexagliflozin group and the comparator 
group at week [ADDRESS_691441] correlation. If the model with the 
unstructured covariance structure does not converge, an autoregressive(1) covariance 
structure will be used.  HbA1c values obtained after the start of rescue medication will  not be 
excluded from  this primary analysis.  Primary endpoint will be analyzed on both intention -to-
treat ( ITT) and per protocol ( PP) analysis sets.  
The MMRM model is one approach to obtain treatment effect estimates in the presence of 
missing data. As sensitivity analyses for  missing data, the following will be performed  on 
both ITT and PP analysis sets : 
1. Missing data will be imputed via multiple imputations , following which the MMRM will 
be repeated on the complete datasets with results combined across com plete datasets 
using standard multiple imputation  techniques; HbA1c values collected after the start of 
rescue medication will not be excluded . 
2. Missing data will be imputed via LOCF, following which the MMRM will be repeated; 
HbA1c values collected after the start of rescue me dication will be considered missing.  
3. HbA1c values collected after the start of rescue medication will be considered missing, 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 12 of 79 Version 3.0  (Global ) and the MMRM analyses will be re -performed.  
 
The effects of bexagliflozin on the changes  from baseline  at week 60 in body weight  and 
systolic blood pressure,  the difference  in the proportion of subjects  with ≥ 1 sever e or 
documented  symptomatic  hypoglycemia event s over 96 weeks and the change  in HbA1c  
from baseline at week 60 will be tested as  key secondary endpoints and will be analyzed in a 
hierarchical testing strategy and only if the primary objectiv e is met . Similar to the primary 
endpoint, ANCOVA models will be used for the continuous secondary endpoints and logistic 
regression model will be used for the binary endpoint . A hierarchical testing strategy will be 
followed to preserve experiment -wide al pha at 0.05:  
1. Superiority test of the change in body weight in subjects with baseline BMI ≥ 25 kg/m2 in 
the bexagliflozin group vs. the  glimepi[INVESTIGATOR_532509] [ADDRESS_691442] of the change in systolic blood pressure (SBP) in subjects with baseline 
SBP ≥ [ADDRESS_691443] of the difference in proportion of subjects with ≥  1 severe or documented 
symptomatic hypoglycemia event  in the bexagliflozin group vs. the  glimepi[INVESTIGATOR_532510] 96 weeks  
 
Additional effects of bexagliflozin  versus glimepi[INVESTIGATOR_532511]1c, FPG, SBP, 
body weight , the proportion of subjects who reach an HbA1c   < 7%, and the proportion of 
subjects with ≥  [ADDRESS_691444] to the change in 
HbA1c from baseline at week 60 by a margin of 0.35%, assuming an estimated pooled 
standard deviation of 1.0 %. This estimation is based on a one-sided t -test with 90 % powe r at 
a 0.025  level of s ignificance. To allow for an estimated 18.0% dropout rate, 210 patients will 
be randomized in each treatment arm , and the total sample size will be 420 subjects for this 
study .  
Statistical analyses and summaries will be performed us ing SAS® software (SAS Institute, 
Cary, NC) .  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 13 of 79 Version 3.0  (Global ) LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
ADA  American Diabetes Association  
AE adverse event  
ALB  albumin  
ALT  alanine aminotransferase  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
ATC Anatomic Therapeutic Chemical classification  
BMI  body mass index  
BP blood pressure  
BUN  blood urea nitrogen  
CEC  cardiovascular endpoint c ommittee  
CFR  Code of Federal Regulations  
CI confidence interval  
CRF  case report form 
CRO  contract research organization  
DKA  diabetic ketoacidosis  
CYP  cytochrome P [ADDRESS_691445] hematocrit  
HCV  hepatitis C virus  
HDL -C high density lipoprotein cholesterol  
HDPE  high-density polyethylene  
Hgb hemoglobin  
HIV human immunodeficiency virus  
ICH International Conference on Harmonisation  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 14 of 79 Version 3.0  (Global ) IEC  independent ethics committee  
IND Investigational New Drug  application  
IRAE  immediately reportable adverse event 
IRB institutional review board 
ITT intention -to-treat 
IWRS  Interactive Web Response System  
LDL -C low density lipoprotein cholesterol  
LOCF  last observation carried forward  
MACE  major adverse cardiovascular event 
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentr ation  
MCV  mean corpuscular volume  
MDRD  modification of diet in renal disease  
MedDRA  medical dictionary for regulatory activities  
MI myocardial infarction  
MMRM  mixed model repeated measures  
MODY  maturity –onset diabetes of the young  
N number of subjec ts 
NYHA  [LOCATION_001] Heart Association  
OHA  oral hypoglycemic agent  
PO per oral  
PP per protocol  
PR time from the beginning of the P wave to the beginning of the QRS 
complex in electrocardiogram  
QRS  QRS complex is a name [CONTACT_532610] a typi[INVESTIGATOR_532512] a measure of the time between the start of the Q 
wave and the end of the T wave in the heart's electrical cycle  
RBC  red blood cell (count)  
SAE  serious adverse event  
SBP systolic blood pressure  
SD standard deviation  
SGLT2  sodium glucose cotransporter [ADDRESS_691446] operating procedure  
 SU sulfonylurea  
S[LOCATION_003]R  serious and unexpected suspected adverse event  
T2DM  type 2 diabetes mell itus 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 15 of 79 Version 3.0  (Global ) TC total cholesterol  
TEAE  treatment emergent adverse event  
TG triglycerides  
TZD  thiazolidinedione  
UACR  urine albumin to creatinine ratio  
UADR  unexpected adverse drug reaction  
UGE  urinary glucose excretion  
ULN  upper limit of normal  
UPT  urinary  pregnancy test  
UTI urinary tract infections  
WBC  white blood cell (count)  
WHO -DD World Health Organization Drug Dictionary  
WOCBP  women of childbearing potential  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 16 of 79 Version 3.0  (Global ) 1 INTRODUCTION  
Type 2 diabetes mellitus (T2DM) is one of the leading causes of morbidity and  mortality 
worldwide, affecting an estimated 415 million people in 2015 . Approximately 187 million of 
those affected are thought to be unaware of their condition and over 80% reside in low - and 
middle -income countries  (IDF 2015 ). 
1.[ADDRESS_691447] 90% of all diabetes 
cases, which is characterized by [CONTACT_532579]. Despi[INVESTIGATOR_532513], the number of people 
with diabetes is projected to increase by [CONTACT_47071] 55% to over 642 million adults by 2040 (IDF 
2015 ). Among the debilitating consequences of T2DM are peripheral neuropathy, 
retinopathy, renal failure, peripheral ischemia and exacerbations of cardiovascular disease, 
which result in blindness, amputation, dialysis and death.  
T2DM is a disease strongly linked to increased body fat mass in the majority of cases 
(Schwartz, Fabricatore et al. 2012 ). Weight loss has been shown to improve glycemic control 
and to reduce the severity of diabetes -associated comorbidities, supporting the view that anti -
diabetic agents that pr omote weight loss may be particularly beneficial for the treatment of 
the disease (Look, Wing et al. 2013 ; Scheen and Van Gaal 2014 ). Several classes of agents 
are available for treating T2DM, including insulin and its secretagogues  such as , 
sulfonylureas (SU) , PPAR agonists, biguanides, alpha glucosidase inhibitors, glucagon -like 
peptide 1 (GLP -1) receptor ag onists, sulfonylureas, meglit inides,  dipeptidyl peptidase 4 
(DPP4) inhibitors , and sodium glucose linked transporter 2 inhibitors (SGLT2i) .  Metformin 
is the first line medication f or treating T2DM; however, as T2DM  progresses  over time , 
metformin monother apy is not able to adequately manage hyperglycemia. T2DM  patients 
often receive more than one antidiabetic medication  after an initial treatment period of 
metformin monotherapy. SU are considered second -line therapy for T2DM in clinical 
practice and are often prescribed with metformin as a combination therapy for treating 
T2DM. SU can reduce the risk of long -term microvascular complications via effective 
glycemic control; however, common side effects include weight gain and increased risk of 
hypoglycemia. The durability of SU treatment can be reduced due to loss of β -cell function 
as T2DM progresses over time.  
The rapid growth rate in the incidence of T2DM has led to an increasing recognition that 
additional therapeutics are needed to provide safe and effect ive reductions of elevated plasma 
glucose levels . New agents to treat T2DM, either as monotherapy or add -on therapy to other 
anti-diabetic medications, would ideally treat hyperglycemia and avoid common side effects 
of currently available agents, such as w eight gain, gastrointestinal disturbance, and 
hypoglycemia.  
The renal Na+/glucose transport protein SGLT2 actively transports extracellular glucose into 
cells using the driving energy of the transmembrane electrochemical potential for sodium 
ions. Individu als with disruptions in SLC5A2 , the gene encoding SGLT2, exhibit prominent 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 17 of 79 Version 3.0  (Global ) glucosuria in the absence of significant co -morbidities (van den Heuvel, As sink et al. 2002 ; 
Santer, Kinner et al. 2003 ). The excretion of glucose in the urine of diabetic subjects in 
amounts comparable to or greater than that seen in individuals harboring loss of functions 
mutations in SLC5A2  has the potential to improve fasting and postprandial hyperglycemia 
without increasin g insulin secretion, causing weight gain, or inducing hypoglycemia. Several 
SGLT2 inhibitors have demonstrated these clinical benefits , as well as sustained weight loss 
when used as a mono -therapy or in combination with other oral anti -diabetic medications  
including insulin (Nauck 2014 ; Seufert 2015 ). 
1.2  Bexagliflozin  for the Treatment of Type 2 Diabete s Mellitus  
Bexagliflozin is a candidate oral hypoglycemic agent (OHA) that is a potent and highly 
specific inhibitor of SGLT2. It was identified following a synthetic program aimed at 
creating molecules with high selectivity and potency for SGLT2 (Zhang, Welihinda et al. 
2011 ). Bexagl iflozin has been shown to cause dose -dependent increases in urinary glucose 
excretion (UGE) in humans, rats, dogs and monkeys and to reduce HbA1c in animal models 
of T2DM as well as in diabetic subjects. The safety and efficacy of bexagliflozin capsules, 
[ADDRESS_691448] infection (UTI) and 
genital mycotic infection (GMI), were similar between placebo and active  agent cohorts. 
Details of the pharmacology, efficacy, and safety assessments are described in the 
Investigator’s Brochure.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 18 of 79 Version 3.0  (Global ) [ADDRESS_691449]  on HbA1c reduction at week 60 in subjects 
whose T2DM is inadequately controlled by [CONTACT_14424] . 
2.2 Key Secondary Objective s 
• To evaluate the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532514] y 
weight in  subjects with baseline body mass index (BMI) ≥  25 kg/m2 at week 60  
• To evaluate the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532515] (SBP) in subjects with baseline SBP ≥  140 mmHg at week 60  
• To evaluat e the treatme nt effect of bexagliflozin vs. glimepi[INVESTIGATOR_532496] ≥ 1 severe or documented symptomatic hypoglycemia event s 
over 96 weeks  
• To evaluate if bexagliflozin is superior to glimepi[INVESTIGATOR_532516]1c reduction at week 60  
 
2.3 Explora tory Objectives  
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532491]1c < 7.0% over time  
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532492]1c 
over time  
• To assess  the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532493] (FPG) over time  
• To assess the treatment effect of bexagliflozin vs . glimepi[INVESTIGATOR_532517] 
• To assess the treatment effect of bexaglif lozin vs. glimepi[INVESTIGATOR_532495]  
• To assess the treatment effect of bexagliflozin vs. glimepi[INVESTIGATOR_532518] ≥  1 severe or documented symptomatic hypoglycemia event s 
over time  
 
Safety Objecti ves: 
• To compare the effects of bexagliflozin vs. glimepi[INVESTIGATOR_532497]. Adverse events of interest are urinary tract infections including 
urosepsis and pyelonephritis, genital mycotic infections, diuretic effects includ ing 
hypovolemia, hypotension epi[INVESTIGATOR_1841], hypoglycemia, hepatotoxicity, major adverse 
cardiovascular events (MACE), falls and fractures, malignancies, hypersensitivity 
reactions, acid -base disorders including diabetic ketoacidosis, and renal failure events . 
• To compare the effects of bexagliflozin vs. glimepi[INVESTIGATOR_532498], clinical laboratory events, 12 -lead 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 19 of 79 Version 3.0  (Global ) electrocardiograms (ECG) parameters, physical examinations, vital signs including 
orthosta tic blood pressure, and use of concomitant medications  
 
Other Objectives:  
• To compare the effects of bexagliflozin and glimepi[INVESTIGATOR_532499] -related quality of life  
using a validated instrument  EQ-5D-3L 
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 20 of 79 Version 3.0  (Global ) 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
THR-1442 -C-480 is a phase 3, multi -center, randomized, dou ble-blind , parallel -group study  
and aims to demonstrate that bexagliflozin is non -inferior to glimepi[INVESTIGATOR_124068] -on therapy  in 
subjects  whose T2DM is not adequately controlled by [CONTACT_532580] . The primary 
efficacy endpoint is the change in H bA1c from baseline at week 60. The study will enroll 
T2DM patients who  are treated with only metformin (metformin -only) or who are treated 
with metformin and one additional oral hypoglycemic agent (metformin -and-OHA)  
All subjects must have taken metformin at a stable dose of ≥ 1500 mg/day for ≥  [ADDRESS_691450] 
received < [ADDRESS_691451] received ≥ 14 
days of no more than 1 other OHA in the  8 weeks prior to screening ; subjects taking any 
other antidiabetic medication (in addition to me tformin and the 1 OHA) for < 14 days in the 
8 weeks prior to screening are allowed .  
A total of  420 subjects who meet all the inclusion criteria, none of the exclusion criteria, and 
who consent to participate in the study , are eligible for study enrollment . Metformin -and-
OHA treated subjects will undergo a 6 -week washout  of the non -metformin OHA  prior to the 
start of run -in. Subjects who  complete the  2-week run -in and who meet all eligibility criteria 
will be randomized in a 1:1 ratio to receive once daily double -blind treatment of either active 
bexagliflo zin tablets  with placebo glimepi[INVESTIGATOR_532519] s (Group 1) or placebo bexagliflozin 
tablets and active glimepi[INVESTIGATOR_532501] (Group 2). Active treatment in Group [ADDRESS_691452] 96 weeks  and be condu cted in an outpatient setting  (Figure 1).   
 
Figure  1. Study Design  
 
3.[ADDRESS_691453] T2DM  often require multiple  anti-

Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 21 of 79 Version 3.0  (Global ) diabetic medications  for glycemic control. S ulfonylurea s are often prescribed with metformin 
as a combination therapy for treating T2DM. Sulfonylureas  can reduce the risk of long -term 
microvascular complications  via effective glycemic control . Yet, c ommon side effects  of 
sulfonylureas include weight gain  and increased risk of hypoglycemia . Glimepi[INVESTIGATOR_532520]-generation sulfonylureas . Thus, it is an appropriate 
active comparator in the subject population studied during the treatment period ( 96 weeks).  
Bexagliflozin is an SGLT [ADDRESS_691454] be taking a stable dose of ≥ [ADDRESS_691455] has taken 
< 1500  mg/day metformin, alone or in combination with [ADDRESS_691456] 1500 mg/day for at 
least [ADDRESS_691457] the long-term effects  of bexagliflozin  compared with glimepi[INVESTIGATOR_14956] .  
3.2.3  Rationale for the Dose Selection  
Bexagliflozin produces a dose -dependent, saturable increase in UGE in healthy volunteers 
and diabetic subjects. Population phar macodynamic modeling has indicated that 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 22 of 79 Version 3.0  (Global ) bexagliflozin doses of 20 mg result in 90% of the maximal UGE. In a long term treatment 
study, daily administration of 20 mg bexagliflozin was found to reduce HbA1c by 0.79% 
compared to placebo at week 24. The treatm ent benefit was observed to improve to 1.02% at 
week 96. FPG reduction, weight loss, and decreased systolic and diastolic blood pressure s 
were also observed following 96 weeks of treatment. In addition, adverse events ( AEs), 
particularly those involving UT I and GMI, were found to be similar between placebo and 
active agent cohorts. To evaluate the safety and efficacy of bexagliflozin for the treatment of 
subjects with T2DM, bexagliflozin tablets, [ADDRESS_691458] 6 
weeks of the study ( Section [IP_ADDRESS] ).  
3.[ADDRESS_691459] will participate in a phone interview visit with 
study staff for SMBG data review and general safety evaluation. Subjects who remain 
eligible at the end of the washout period will begin a two -week run -in period.  
Metformin -only treated subjects will not undergo washout ; they will proceed directly to the 
start of run -in. At the start of the run -in period, metformin -only treated subjects will receive 
diet and exercise counseling as well as instructions on contact[CONTACT_532581], hypoglycemia, or symptoms that may suggest ketoacidosis. Metformin -and 
OHA treated subjects will receive  this information at the start of the washout period. At the 
start of run -in, m etformin -only treated subjects will be provided with a glucometer and 
instructions for its daily use.  
All eligible subjects who are metformin -only treated or have successfully completed the [ADDRESS_691460] meal; t he 
medications should be taken with water.  Metformin dose and frequenc y will remain 
unchanged from time of screening throughout the course of the study.  
Subjects will not be eligible for randomization if during  the run -in period they:  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 23 of 79 Version 3.0  (Global ) 1. have fasting blood g lucose values  ≥ 250 mg/dL on two or more consecutive days,  
2. omit more than [ADDRESS_691461] an HbA1c value ˂ 7.0% or ˃ 10.5%  at visit V5 . The glycemic contro l requirement 
based on HbA1c values is outlined in  Figure [ADDRESS_691462] will be considered as screen failed and disconti nue study activities ; the subject  
may be re -screened as a new subject after the clinical condition and treatment regimen have 
not changed for at least [ADDRESS_691463] will 
be considered as scr een failed and discontinue study activities; there will be no opportunity to 
re-screen for subjects who have started run -in or failed  screening.   
3.3.[ADDRESS_691464] 96 weeks. A total of  
420 subjects of 210 subjects per group will be randomized in a 1:1  ratio to the two groups  as 
shown in Table 1 .  

Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 24 of 79 Version 3.0  (Global ) Table  1. Treatment Groups and Assigned Treatment  
Treatment Gro up Treatment  
1 Bexagliflozin  tablets, 20 mg , (once daily P.O.)  
Glimepi[INVESTIGATOR_532501], placebo , (once daily P.O.)  
2 Bexagliflozin tablets, placebo,  (once daily P.O.)  
Glimepi[INVESTIGATOR_532501], 2, 4 or 6 mg , (once daily P.O.)  
 
Randomization will be stratified b y HbA1c at Visit V5 (≤ 8.5% vs. ˃ 8.5%), treatment 
background (metformin -only vs. metformin -and-OHA),  and baseline estimated glomerular 
filtration rate ( eGFR ) at screening visit (V1) (eGFR ≥  90 vs. < 90 and ≥ 60 mL/min/1.73 m2). 
At the start of the treatment period, each subj ect will be provided with bexagliflozin tablets, 
glimepi[INVESTIGATOR_532501],  dosing instruction s, and a glycemic control diary in which to record 
SMBG measurements. Symptoms and blood sugars  related to th e occurrence of 
hyperglycemi a, hypoglycemic events or symp toms that may suggest ketoacidosis will be 
recorded.  Bexagliflozin tablets, [ADDRESS_691465] meal; glimepi[INVESTIGATOR_532501], 2, 4, or [ADDRESS_691466] will be instructed t o return to the clinic at weeks 0, 2, 4, 6, 12, 24, 36, 48, 60, 
72, 84 (off -site phone visit)  and 96 for efficacy assessment and safety monitoring, including 
review of adverse events and concomitant medication, vital signs, ECG, physical 
examination, and blood and urine specimen collections. On the day of a clinic visit  at which 
blood samples are sch eduled to be collected , approximately  10 hours (h) fasting must be 
confirmed prior to blood draw. On the day of the scheduled clinic visits  at which there is 
fasting and blood is to be drawn , administration of bexagliflozin shall be wit hheld until after 
blood is drawn  and taken with water at the clinic or home  prior to the first meal;  glimepi[INVESTIGATOR_532521].  
Subjects will return to the clinic for a follow -up exit visit at week [ADDRESS_691467] s early terminate  prior to week 96 . Following the exit visit, 
subjects will be advised to see their primary physician to undergo treat ment to control their 
diabetes.  
[IP_ADDRESS]  Glimepi[INVESTIGATOR_532522], glimepi [INVESTIGATOR_532523]: 2 mg, 4 mg, 
and 6 mg. Glimepi[INVESTIGATOR_532524] .  
Weeks 0 to 6   
Subjects will receive the starting dose of glimepi[INVESTIGATOR_532525] 2 mg or placebo  at week 0 (V6) .  
At weeks 2, 4 and 6 ( scheduled visits V7, V8 and V9 , respectively ), subjects will return to 
the clinic for  the assessment of glimepi[INVESTIGATOR_532526]-titration  and safety evaluation . If subjects 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 25 of 79 Version 3.0  (Global ) meet the following glycemic criteria  in the preceding 2 weeks , glimepi[INVESTIGATOR_532527].  
1. ≥ 50% of documented fasting SMBG measurements ˃ 110 mg/dL  (6.1mmol/L ) 
2. no severe or documented symptomatic hypoglycemia events  
 
Subjects assigned to receive placebo glimepi[INVESTIGATOR_14956], will receive mock titrations of glimepi[INVESTIGATOR_532528] 2, 4, and 6 based on the s ame glycemic criteria.  
In case of persistent hyperglycemia [more than 3 consecutive daily, fasting SMBG measures 
≥ 270 mg/dL (15mmol/L)]  during the treatment period , subjects should cont act the clinic and 
schedule the up-titration visit (s) early  to receiv e the next higher dose of glimepi[INVESTIGATOR_14956] . 
During weeks 0 to 6, each up -titration visit should be conducted no more than 2 weeks after 
the prior visit. Visits V6 and  V9 will always occur at week 0 and week 6, respectively.  
In the case that subjects experience  persistent hyperglycemia and up-titration visits are 
scheduled early, i f more than two weeks elapse between scheduled visits  or an up -titration is 
needed between scheduled visits , an unscheduled visit with the same study procedures and 
tests as  the previo us scheduled visit will be conducted  during the unscheduled visit .  
If subjects do not meet up -titration glycemic  criteria, subjects will continue glimepi[INVESTIGATOR_532529].  The up -titration schema is demonstrated in  
Figure 3 . 
Weeks  7 to 96 
No dose change s in glimepi[INVESTIGATOR_532530] 6 weeks of treatment.  Subjects will continue 
receiving  glimepi[INVESTIGATOR_532531], time, and frequency  prescribed to them at 
week  6. 
Down -titration o f glimepi[INVESTIGATOR_532532].   
At the discretion of the investigator, s ubjects who experience recurring  symptomatic 
hypoglycemia or any severe epi[INVESTIGATOR_532533].  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 26 of 79 Version 3.0  (Global )  
*If su bjects have persistent hyperglycemia [more than 3 consecutive daily, fasting SMBG measures 
≥ 270 mg/dL (15mmol/L)], subjects should contact  [CONTACT_532582] -titration visit(s) 
early to receive the next higher dose of glimepi[INVESTIGATOR_532534]  3. Glimepi[INVESTIGATOR_532535] -titration Flow Chart  
 
3.3.3  Glycemic Control Monitoring  
[IP_ADDRESS]  Wash -out Period  and Placebo Run -in Period  
During the  wash -out and placebo run -in period, subjects will be instructed to determine 
SMBG daily after fasting overnight for a minimum of [ADDRESS_691468] the clinic  
if any fasting glucose value is  ≥ 250 mg/dL (13.9 mmol/L) , and the investigator will 
determine whether the participant should attempt to improve diet and exercise  to maintain 
glycemic control or if the participant must withdraw from the study and initiate a more 
intense pharmacological r egimen for glucose control.   
A subject will be excluded from further participation if his fasting blood glucose is 
≥ 250 mg/dL  prior to randomization on [ADDRESS_691469], increased urination, or fatigue , should also be 
excluded.  
[IP_ADDRESS]  Treatment Period  
During the treatment period, subjects will be advised to continue daily, fasting SMBG 
measureme nts. Subjects should contact [CONTACT_532583] ≥ 270 mg/dL  
(15 mmol/L ) from week baseline  to week 6, ≥  240 mg/d L (13.3 mmol/L ) after week 6 to 
week 12, or ≥  200 mg/d L (11.1 mmol/L ) after week 12. Blood glucose values collected via 
SMBG will be evaluated at study visits by [CONTACT_32595]. In addition, hyperglycemia will 
be monitored by [CONTACT_532584]. 

Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 27 of 79 Version 3.0  (Global ) If hyperglycemia is identified through SMBG or FPG measurements, the investigator will 
determine whether the subject has fasted for a minimum of [ADDRESS_691470]. Options 
for intensification of medical therapy will vary during the study, including up -titration of 
glimepi[INVESTIGATOR_532536] (week s 0-6) and addition of rescue medication  (see below, Intensification of 
Medical Therapy for Hyperglycemia ).  
[IP_ADDRESS]  Intensification of Medical Therapy for Hyperglycemia  
During the entire treatment period,  a review of diet and exercise counseling is suggested 
prior to prescription of rescue medication in the absence of specific medical indications for 
rescue medication.  
Intensification of medical therapy  for hyperglycemia  is suggested during the treatment period 
if, after diet and exercise counseling,  subjects meet the following glycemic criteria :  
1. More than 3 consecutive, daily, fasting SMBG meas ures are ≥ 270 mg/dL  (15 mmol/L ) 
from baseline  to week 6, ≥  240 mg/dL  (13.3 mmol/L ) after week 6 to week 12, or 
≥ 200 mg/dL  (11.1 mmol/L ) after week 12 to week 96  
2. Fasting SMBG values  are ≥ 250 mg/dL  (13.9 mmol/L ) and associated with clinical signs 
or sympt oms of hyperglycemia ( e.g., weight  loss, blurred vision, increased thirst, or 
increased urination, or fatigue), and the signs or symptoms are severe  
 
From week 0 to week 6, up -titrating glimepi[INVESTIGATOR_532537] . If necessary, increases 
in glimepi[INVESTIGATOR_532538]. The criteria for glimepi[INVESTIGATOR_532539]-titration are  provided in Section [IP_ADDRESS] . After glimepi[INVESTIGATOR_532540] -titration  to the maximal 
level , rescue medication should be initiated  for treating hyperglycemia  based on 
investigator’s assessment . 
After week [ADDRESS_691471] ’s glycemic control will be impacted by [CONTACT_532585] . 
The investigator may provide rescue treatment with any approved medi cation for diabetes 
that is not otherwise contraindicated, with the exception of SGLT2 inhibitor, sulfonylurea  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 28 of 79 Version 3.0  (Global ) and metformin , as all study subjects will already be taking metformin and may be taking 
active SGLT2 inhibitor or glimepi[INVESTIGATOR_532541].  
If hypoglycemia occurs in any subject who has been prescribed rescue medication for 
hyperglycemia during the study, the total daily dose of the rescue medication should be 
reduced 50% or more at the discretion of the investigator. If recurrent s ymptomatic 
hypoglycemia occurs after discontinuation of the rescue medication or in subjects who are 
not prescribed rescue medication, study drug can be discontinued at the discretion of the 
investigator.  
Subjects who receive rescue medication due to poor glycemic control will continue to receive 
investigational product s and standard of care per investigator decision, according to current 
treatment guidelines . Following the exit visit, subjects will be advised to see their primary 
physician to undergo treat ment  to control their diabetes.  
3.3.[ADDRESS_691472] be appropriately documented within source documentation.  
• Genital mycotic infection  
• Urinary tract infections including urosepsis and pyelonephritis  
• Acid-base disorders  including diabetic ketoacidosis  
• Diuretic effects including hypovolemia  
• Hypotension epi[INVESTIGATOR_1841]  
• Hepatotoxicity  
• MACE  
• Hypoglycemia  
• Falls and fractures  
• Malignancies  
• Hypersensitivity reactions  
• Renal failure events  
• Amputation  
 
3.3.[ADDRESS_691473] (DSMB)  
An independent Data and Safety Monitoring Board (DSMB) will monitor overall safety 
information during the bexagliflozin  development program. The safety review activity and 
potential risk benefit assessments utilized by [CONTACT_532586] b e defined in its charter.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 29 of 79 Version 3.0  (Global ) 3.3.6  Major Adverse Cardiovascular Event (MACE) Adjudication  
An independent cardiovascular adjudication committee has been  established to review,  under 
blind,  all potential cardiovascular events occurring during the study . The events of interest 
include cardiovascular mortality, myocardial infarction  (MI) , stroke, hospi[INVESTIGATOR_532542], urgent revascularization procedures, and other possible serious 
cardiovascular events . The adjudicated events will be documented and archived to allow a 
meta -analysis to be performed at a later time . No separate cardiovascular risk assessment will 
be performed based on events in the study population of the current protocol.  
3.3.7  Diabetic Ketoacidosis (DKA) Event Adjudication  
An independ ent adjudication committee will be established to review all potential diabetic 
ketoacidosis events under blind. The adjudicated events will be documented and archived. 
All adjudicated DKA events in the bexagliflozin phase [ADDRESS_691474] dosing . The study duration from 
screening to follow -up will be no more than 109 weeks overall. For details of the schedule 
and nature of the investigations, see the Schedule of Events in Appendices 1  and 2.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 30 of 79 Version 3.0  (Global ) [ADDRESS_691475] be:  
1. Male or female adult subjects ≥ [ADDRESS_691476] and agree to abstain from coitus or use contraception during the entire 
study to avoid any possible pregnancy .  
3. Subjects who are in one of the two categories:   
a) Metformin -only treated: receive ≥ 1500 mg/day metformi n only for at least 8 
weeks prior to screening  or  
b) Metformin -and-OHA treated: receive ≥ 1500 mg/day metformin for at least 8 
weeks  prior to screening  and ≥  14 days of 1 additional oral hypoglycemia 
agent (OHA) in the 8 weeks prior to screening.  
4. Subjects with a diagnosis of T2DM with HbA1c levels between 7.0% and 10.5% 
(inclusive) at screening if metformin -only treated or with HbA1c levels between 6.5 % 
and 10.0% (inclusive) at screening if metformin -and-OHA treated  
5. Subjects have a body mass index (BMI) ≤ 45 kg/m2 at screening  
6. If applicable, taking stable doses of treatment for dyslipi[INVESTIGATOR_83281]/or hypertension for 30 
days prior to screening. Subjects do not need to be treated with dyslipi[INVESTIGATOR_532543].  
7. Subjects who are w illing and able to return for all clinic visits and to complete all study -
required procedures, including self -monitoring blood glucose (SMBG) measurements  
 
Prior to randomization, all subjects must : 
8. Maintain adequate glycemic control during the washout and  run-in periods  (fasting 
plasma glucose values are not ≥ 250 mg/dL on consecutive days)  
9. Have an HbA1c between 7.0 % and 10.5% (inclusive)  at Visit V5  
10. Adhere to the investigational product administration requirements as evidenced by 
[CONTACT_532578] 2 doses  of run -in medication s 
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 31 of 79 Version 3.0  (Global ) 4.3 Exclusion Criteria  
Subjects  who exhibit any of the following characteristics will be excluded from the study:  
1. Diagnosis of type 1 diabetes mellitus or maturity –onset diabetes of the young (MODY)  
2. Current use of injected therapy for treatment of diabetes (insulin or glucagon -like 
peptide-1 (GLP -1) receptor agonist therapy)  or a thiazolidinedione  (TZD)  
3. Hemoglobinopathy that affect s HbA1c measurement  
4. Any contraindication to the safe use of sulfonylurea  therapy , glimepi[INVESTIGATOR_532544] , 
including known hypersensitivity reaction   
5. Genitour inary tract infection within 6 weeks of screening or history of ≥  3 genitourinary 
infections requiring treatment within 6 months from screening  
6. Cancer , active or in remission , for  < 3 years (non -melanoma skin cancer or basal cell 
carcinoma or carcinoma  in situ of the cervix will not be grounds for exclusion)  
7. History of alcohol or illicit drug abuse in the past 2 years  
8. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x 
upper limit of normal (ULN) with the exception of  isolated Gilbert’s syndrome); or 
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.[ADDRESS_691477]  
9. Estimated glomerular filtration rate (eGFR), as calculated by [CONTACT_532587] e study equation (MDRD), <  60 mL/min/1.73  m2 at screening . 
10. Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood 
pressure > 95 mmHg) at Visit V1  
11. History of human immunodeficiency virus (HIV) infection  
12. Life expectancy < 2 years  
13. History of m yocardial infarction  (MI) , unsta ble angina, stroke, or hospi[INVESTIGATOR_144338] 3 months of screening  
14. History of t reatment with an investigational drug within 30 days or within 7 half-lives  of 
the investigational drug, whichever is longer  
15. Previous treatment with bexaglifl ozin or EGT0001474  study drug ( run-in or double -blind 
investigational product)  
16. Currently or within 3  months of taking any SGLT2  
17. Currently participating in another interventional trial  
18. Prior renal transplantation or evidence of nephrotic syndrome (defined as a urine 
albumin -to-creatinine ratio (UACR) > 1500  mg/g at screening).  
19. Any condition, disease, disorder, or clinically relevant abnormality that, in the opi[INVESTIGATOR_532545], would jeopardize the subject’s appropriate participation in this  
study or obscure the effects of treatment  including condition or co -morbidity for which 
the use of metformin or any planned or existing second diabetes therapy is 
contraindicated  
20. Female subjects who are pregnant or nursing.  
21. Two or more consecutive  SMBG  measures ≥ 250 mg/dL (13.9 mmol/L) prior to 
randomization or severe clinical signs or symptoms of hyperglycemia prior to 
randomization , including weight loss, blurred vision, increased thirst, or increased 
urination, or fatigue . 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 32 of 79 Version 3.0  (Global ) [ADDRESS_691478]  
Bexagliflozin tablets, 20 mg or placebo, are blue caplet -shaped, film -coated tablets that are 
intended for use in investigational studies in humans. The tablets contain excipi[INVESTIGATOR_532546] t hrough a gastroretentive mechanism. The active tablets exhibit 
a greater than 75% re lease of drug substance by 8 h in simulated gastric fluid in vitro .  
The following investigational products will be used for oral administration:  
• Bexagliflozin tablets, 20 mg: tablets containing 20 mg of bexagliflozin  
• Bexagliflozin tablets, placebo: tablets containing no bexagliflozin  
 
5.1.2  Active Comparator  
Glimepi[INVESTIGATOR_532547] , 2 mg, 4 mg, 6 mg or placebo , are orange colored capsules.  
The following investigational drugs will be  used for oral administration:  
• Glimepi[INVESTIGATOR_532501],  2 mg: capsules  containing 2 mg of  glimepi[INVESTIGATOR_14956]  
• Glimepi[INVESTIGATOR_532501] , 4 mg: capsules  containing 4 mg of glimepi[INVESTIGATOR_14956]  
• Glimepi[INVESTIGATOR_532501] , 6 mg: capsules containing 6 mg of glimepi[INVESTIGATOR_14956]  
• Glimepi[INVESTIGATOR_532548], placebo: capsules  containing no glimepi[INVESTIGATOR_14956]  
 
5.[ADDRESS_691479]. Glimepi[INVESTIGATOR_532549] P450 enzyme CYP2C9.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 33 of 79 Version 3.0  (Global ) Glimepi[INVESTIGATOR_532501], 2, [ADDRESS_691480] -line agent for treating T2DM . It is a biguanide 
that decreases hepatic glucose production and may improve peripheral glucose uptake and 
utilization. After oral administration, metformin  is absorbed from the g astrointestinal (GI) 
tract, and  it is excreted unchanged in the urine and does not undergo hepatic metabolism or 
biliary excretion.  
Any OHA  other than metformin taken by [CONTACT_532588] -out period . Subjects will continue receiving metformin 
as background therapy during the entire study period at an unchanged dose (≥  1500  mg/day), 
time, and frequency that is prescribed to subjects prior to screening.  
The dose, frequency, and time of administra tion should remain stable unless the investigator 
deems adjustment (decrease or increase) necessary for the medical well -being of the subject. 
Changes to the dose, frequency, or time of administration of metformin should be recorded in 
the concomitant medi cation log.  
5.2.[ADDRESS_691481] 2 weeks of therapy. Changes to the dose 
or frequency of anti -hypertensive and d iuretic medications will be recorded in the 
concomitant medications log.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 34 of 79 Version 3.0  (Global ) 5.[ADDRESS_691482] meal ; bexagliflozin tablets  should be taken once daily P.O. with 
[ADDRESS_691483] 
6 weeks of treat ment  according to the protocol -specific criteria  (Section [IP_ADDRESS] ). From weeks  
7 to 96 , subjects will continue receiving glimepi[INVESTIGATOR_532550] 6. 
Down titration  of glimepi[INVESTIGATOR_532551].  
5.4 Method of Assigning Treatment Groups  and Study Drugs  
The study will be cond ucted at multiple investigative sites and will likely involve variable 
numbers of subjects at each site. Enrollment will be on a competitive basis , but each site will 
be capped at 40 randomized  subjects. Activation of investigational sites in each country will 
be centrally controlled by [CONTACT_53804] (IWRS).  
Eligible subjects who complete the wash -out and run-in period and meet all study 
inclusion/exclusion requirements will be randomized in a 1: 1 ratio to receive active 
bexagliflozin  with placebo glimepi[INVESTIGATOR_532552] . 
Subjects will be assigned to treatment groups in sequential order as they qualify for the study . 
Randomization will be stratified according to baseline (Visit V5) HbA1c (< 8.5% or ≥ 8.5%) , 
treatment background  (metformin -only or metformin -and-OHA) , and Visit V5 eGFR  (≥ 90 
or ˂ 90 and ≥ 60  mL/min/1.73  m2). 
The investigator or designated staff will log in to the IWRS to receive the following 
information:  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 35 of 79 Version 3.0  (Global ) Table  2. Study Drug Dispensation Schedule  
Visit  Unique ID  Run-in Drugs  Bexagliflozin Tablets 
(no. of kits)  Glimepi[INVESTIGATOR_532553] (no. 
of kits)  
V1 Subject no.     
V4  bexagliflozin & 
glimepi[INVESTIGATOR_14956]    
V6 Randomiza tion 
no.  20 mg or placebo (1)  2 mg or placebo (1)  
V7 to V91    4 mg, 6 mg or plac ebo (1)  
V10 to V14    20 mg or placebo (1)  2, 4 or  6 mg or placebo 
assigned at Week 6 (1)  
V15   20 mg or placebo (2)  2, 4 or  6 mg or placebo 
assigned at Week 6 (2)  
[ADDRESS_691484] the glimepi[INVESTIGATOR_532554] . The up-titration  of 
glimepi[INVESTIGATOR_532555] . The 
guidance for glimepi[INVESTIGATOR_532540]-titration  is outlined in Section [IP_ADDRESS] . 
 
Subject randomization will be deactivated for all sites when the planned number of subjects 
is met . However, if a potential subject is in wash -out already and wishes to continue with the 
study, the subject will be allowed to continue an d, if eligible, to be randomized . 
5.[ADDRESS_691485]’s condition, the investigator will contact [CONTACT_532589]. If unblinding occurs for any reason, the time and reason 
for breaking the blind will be recorded on the case report form (CRF) and the sponsor must 
be notified with in [ADDRESS_691486] be submitted to regulatory agencies .  
The treatment assignment will continue to be withheld  from the cardiovascular adjudication 
committee and diabetic ketoacidosis adjudication committee members  until all global 
investigational studies are completed and  final analyses to assess cardiovascular and 
ketoacidosis risks are conducted.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 36 of 79 Version 3.0  (Global ) 5.[ADDRESS_691487] of care guidance documents for the 
management of T2DM. Instructions for intensification of medical therapy for hyperglycemia 
are provided in Section [IP_ADDRESS] . Instructions and requirements for adjustment to diuretics and 
treatment for dyslipi[INVESTIGATOR_532556] 5.2.4 . Subjects will be 
allowed to take medications or medicinal supplements prescribed to manage non -diabetic 
medical conditions during the study. Any conc urrent medication or supplemental treatment 
of other, non -diabete s, medical  conditions should be continued at a stable dose and frequency 
for the entire study duration unless there is a clinical reason to change the dose or frequency.  
Subjects may receive any medications for adverse events that are necessary in the 
investigators’ judgment. Concomitant medications prescribed at the time of the  wash -out and  
run-in period and during the study are to be recorded on the CRF. The medication name, 
dose, frequency, route of administration, date(s) of administration and reason f or 
administration must be recorded. This documentation should continue through the treatment 
period and the follow -up period.  
Any medication prescribed to a subject after enrollment and prior to randomization, 
including contraceptives, must be recorded in  the CRF.  
5.[ADDRESS_691488] for approximatel y 10 h prior to the scheduled blood sample draws. During 
fasting, only water will be permitted.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 37 of 79 Version 3.0  (Global ) 5.7.[ADDRESS_691489] 150 min/week of moderate activity is advised by [CONTACT_23319] (ADA) (American Diabetes, 2014 ). Alternatively, local  
regulatory  guidelines may be used.  
5.[ADDRESS_691490] or designated s ite personnel in 
high-density polyethylene ( HDPE ) bottles of [ADDRESS_691491] according to randomization assignment.  
5.9.1  Run-in Kit s 
Two types of run -in kits are provided:  
• Bexagliflozin  tablets, placebo , 15 tablets per bottle;  
• Glimepi[INVESTIGATOR_532501] , placebo , [ADDRESS_691492] number,  investigator name, storage 
condition, directions for use, sponsor’s name [CONTACT_3816], and the investigational drug 
caution statement.  
5.9.[ADDRESS_691493] bo.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 38 of 79 Version 3.0  (Global ) The label attached to each bexagliflozin  kit will contain the protocol number, product 
identification, kit number, batch number, expi[INVESTIGATOR_320], subject number, investigator name, 
storage condition, directions for use, sponsor’s name [CONTACT_3816], and  the investigational 
drug caution statement.  
5.9.3  Glimepi[INVESTIGATOR_532557] a 90 count  bottle  of one of the following products:  
• Glimepi[INVESTIGATOR_532501] , 2 mg  or placebo  
• Glimepi[INVESTIGATOR_532501], 4 mg or placebo  
• Glimepi[INVESTIGATOR_532501], [ADDRESS_691494] number, investigator name, 
storage condition, directions for use, sponsor’s name [CONTACT_3816], and the i nvestigational 
drug caution statement.  
5.10 Storage and Accountability  
Bexagliflozin  tablets  and glimepi[INVESTIGATOR_532558] 15°C to 30°C (59°F to 86°F). The sponsor will notify the sites of the process for returning 
unused drug.  
5.[ADDRESS_691495] be returned to a sponsor -designated depot 
after drug accountability is verified by [CONTACT_12409].   
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 39 of 79 Version 3.0  (Global ) [ADDRESS_691496] is 
aware of the potential risks, inconveniences, or adverse events ( AEs) that may occur. The 
investigator should educate potential subjects about the scientific importance of their data 
and the vital role that their participation has for the outcome of the entire s tudy. The subject 
must be informed that he/she is free to withdraw from the study at any time. He or she will 
receive all information that is required by [CONTACT_532590] ( ICH) guidelines.  
The informed consen t document must be signed and dated; one copy will be given to the 
patient, and the investigator will retain a copy as part of the clinical study records. The 
investigator will not undertake any investigation specifically required for the clinical study 
until written consent has been obtained. The terms of the consent and when it was obtained 
must also be documented.  
6.2 Screening for I/E Criteria  
At the initial screening, the investigator should review the inclusion and exclusion criteria 
based on the informa tion collected at the screening visit. Any change to status affecting 
conformance to inclusion and exclusion criteria at subsequent visits prior to randomization  
must be evaluated . At randomization, the investigator should confirm the run -in drug 
complianc e. 
6.3 Medical History  
The following information will be collected at the screening visit:  
6.3.[ADDRESS_691497] is of childbearing potential 
or not.  
2. Significant medical and s urgical history, including dates of diagnoses and procedures and 
whether the condition is ongoing, if applicable.  
 
6.3.2  Diabetes History  
1. History of all medications used to treat diabetes (to be recorded in the concomitant 
medication form), including start date , duration of use, and stop date, if applicable.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 40 of 79 Version 3.0  (Global ) 2. History of complications due to diabetes, including nephropathy, retinopathy, 
neuropathy, non -traumatic amputations, and diabetic ketoacidosis, including date of 
diagnosis  
3. Frequency of hypoglycemic events (p er week) that are symptomatic or require assistance.  
 
6.3.3  Cardiovascular Disease History  
History of cardiovascular disease including presence of angina, congestive heart failure 
(including [LOCATION_001] Heart Association [ NYHA ] classification), known atherosclerot ic 
cardiovascular disease, prior MI, transient ischemic attack or stroke, and prior cardiac or 
peripheral re -vascularization procedures. The history should include the date of diagnosis and 
the current status of diagnosis (resolved or ongoing).  
6.3.[ADDRESS_691498] 30 days prior to screening. Each medication history 
will include the agent used, indication for usage, start and stop dates, dose, and 
frequency.  
 
6.4 Diet and Exercise Counseling  
Subjects will receive counseling regarding an appropriate  diet and exercise regimen to aid in 
glycemic control based on standards of medical care in diabetes throughout the study. In 
addition, all subjects are encouraged to consume enough liquid to maintain adequate 
hydration.  
6.5 Physical Examination  
A complete ph ysical examination will be performed by [CONTACT_397922] ( Appendix 1 ). The examination will include 
measurement of body weight and height (height will be measured only at  screening), general 
assessment of all body systems including the skin, head, eyes, ears, nose, throat, neck, heart, 
lungs, abdomen, lymph nodes, and extremities.  
The body weight must be determined using a scale that is calibrated. The same scale should 
be used throughout the study duration.  
6.6 Abbreviated Physical Examination  
An abbreviated physical examination will include body weight and general assessment of the 
skin, heart, lungs and abdomen. Abbreviated physical examinations will be performed by [CONTACT_532591] ( Appendix 1 ), unless 
clinically indicated.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 41 of 79 Version 3.0  (Global ) The body weight must be determined using a scale that is calibrated. The same scale should 
be used throughout the stu dy duration.  
6.7 Vital Signs  
Vital signs will be measured at the time points indicated in the Schedule of Events 
(Appendix  1) and will include supi[INVESTIGATOR_050], sitting and standing BP measurements, and heart rate.  
Devices designed to mea sure BP from the finger or wrist may not be used. The left arm and 
same cuff sizes should be used for each measurement at all visits. If the left arm cannot be 
used at the screening visit or during the study for BP measurements, the reason should be 
docume nted, and the right arm should be used for BP measurements for all subsequent visits.  
At each visit, BP measurements will be obtained using a calibrated sphygmomanometer 
while the subject is in sitting, supi[INVESTIGATOR_050], and standing positions. A single heart rate m easurement 
should be taken just prior to the BP evaluation in the sitting, supi[INVESTIGATOR_050], and standing positions.  
All readings are to be entered into the source document and CRF for all subjects. The date 
and time of BP measurements should be captured in the sou rce document and CRF. BP will 
be assessed first in the sitting position. Sitting BP and heart rate will be measured after the 
subject has been sitting for at least [ADDRESS_691499] abnormalities or arrhythmia.  
It is the investigator’s responsibility to review the results of the ECG as they become 
available. For each abnormal ECG result, the investigator shall ascertain if the observation 
represents a clinically significant change from the screening ECG for that individual subject . 
This determination  does not necessarily need to be made the first time an abnormal result is 
observed . The investigator may repeat the ECG to verify the original result. If the ECG result 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 42 of 79 Version 3.0  (Global ) is determined to be a clinically significant and abnormal change from baseline for that 
subject, it is considered to reflect an AE.  
 
6.9 Clinical Laboratory Tests  
6.9.1  Laboratory Parameters  
Clinical laboratory tests are listed in  Table 3. 
6.9.2  Sample Collection, Storage, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Hematology, Blood Chemistry, Serum Lipi[INVESTIGATOR_805], and Glycemic Control 
Assessments  
Blood samples for hem atology, chemistry, serum lipi[INVESTIGATOR_272208]. Subjects will be in a seated or supi[INVESTIGATOR_2526]. 
Samples will be collected at the time points indicated in the schedule of events in Appendix [ADDRESS_691500] return as soon as can be arranged (within 1 week) to 
provide a specimen after proper fasting.  
Low-density lipoprotein -cholesterol  (LDL -C) will be calculated by [CONTACT_6459]. 
If triglycerides are > 400 mg/dL, the calculated LDL -C value is invalid by [CONTACT_532592]. Direct LDL -C will be determined in subjects whose triglycerides are 
> 350 mg/dL at screening visit. All subsequent LDL -C of these subjects will be determined 
by [CONTACT_272292] -C measureme nts only.  
[IP_ADDRESS]  Urinalysis  
Urine samples will be collected routinely at designated clinic visits from a clean catch 
sample. Urinalysis will be performed at the time points indicated in the schedule of events 
(Appendix 1  and Appendix 2 ). Investigator or staff should document if pre -menopausal 
female subjects are menstruating and note it in the source documents since hematuria is 
likely to be identified  on dipstick urinalysis.  
Urine samples will be transported to the central laboratory for urinalysis. Microscopy will be 
conducted if the subject has a positive result on the leukocyte esterase or nitrite dipstick tests 
to clarify the significance of the fi nding. Results of glucose measurement in the urinalysis 
must be suppressed from the laboratory reports so the sponsor, investigators, study 
coordinators, pharmacists, study subjects, the cardiovascular endpoint committee ( CEC ) 
members  and (diabetic ketoaci dosis) DKA adjudication  committee members  will remain 
blinded to the dosing assignment.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 43 of 79 Version 3.0  (Global ) In addition, strips to assess leukocyte esterase and nitrite but not glucose will be provided for 
immediate assessment at the clinical sites. If more than traces of pos itive results are shown in 
the leukocyte esterase and /or nitrite testing, a urine culture should be performed in 
a designated laboratory regardless of patient reported signs or symptoms. Results of the 
urinalysis and possible urine culture will be documen ted in the CRFs.  
Renal functional testing by [CONTACT_532593] ( Appendix 1  and Appendix  2).  
[IP_ADDRESS]  Urine Pregnancy Test (UPT)  
UPT will be performed for all women, including surgically sterile or post -menopausal 
women, at the screening visit. Additionally, women of child bearing potential (WOCBP) will 
receive a UPT at the clinical visits indicated  in Appendix 2 . 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 44 of 79 Version 3.0  (Global ) Table  3. List of Laboratory Tests  
Test Name  (sample volume)   
Hematology (2 mL blood)   
• Mean corpuscular hemoglobin 
(MCH)  
• Mean corpuscular hemoglobin 
concentration (MCHC)  • Mean corpusc ular volume (MCV)  
• White blood cell (WBC) count 
with differential  
• RBC Morphology  • Red blood cell (RBC) count  
• Hematocrit (Hct)  
• Hemoglobin (Hgb)  
• Platelet count  
Serum Chemistry and Electrolytes (3 mL serum)   
• Albumin (ALB)  
• ALT  
• AST  
• Blood urea nitrogen (BUN)  
• Creatinine  
• Uric acid  • Calcium (Ca)  
• Magnesium  
• Phosphorus  
• Potassium (K)  
• Sodium (Na)  
• Total Protein  • Glucose  
• Bicarbonate (HCO 3) 
• Chloride (Cl)  
• Total bilirubin  
• Direct bilirubin  
 
Glycemic Control (2 mL plasma, 2 mL blood)  
• FPG • HbA1c   
Serum Lipi[INVESTIGATOR_805]   
• Total chole sterol (TC)  
• High -density lipoprotein cholesterol 
(HDL -C) • Low-density lipoprotein 
cholesterol (LDL -C), calculated, 
or  
• LDL -C, direct  (if applicable)  • Triglycerides (TG)  
Urinalysis  
• Appearance  
• Bilirubin  
• Color  
• Glucose (blinded)  
• Ketones  • Microscopic examination  of 
sediment  
• Nitrite  
• Leukocyte esterase  
• Occult blood  • pH 
• Protein  
• Specific gravity  
• Urobilinogen  
 
Renal Functional Test  
• UACR    
Urine Pregnancy Test  
 
6.[ADDRESS_691501] be downloadable so that SMGB records can be kept for 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 45 of 79 Version 3.0  (Global ) the evaluation by [CONTACT_093] . The SMBG record from the glucometer and diary entries 
must be reviewed by [CONTACT_532594].  
During the SMBG training, symptoms that may indicate hypoglycemia, hyperglycemia, or 
ketoacidosis will be reviewed with study subjects. Instructions to contact [CONTACT_532595].  
6.[ADDRESS_691502] by [CONTACT_941] I WRS. At visit V15, two bottles of bexagliflozin tablets will be 
dispensed for dosi ng between week 72 and week 96 .  
6.13.2  Dispensing Glimepi[INVESTIGATOR_532559] 0 to 6  
• Each subject  will rece ive 1 bottle of glimepi[INVESTIGATOR_532547] , 2 mg or placebo, at 
randomization . 
• During wee ks [ADDRESS_691503] the glimepi[INVESTIGATOR_532560] . The guidance for glimepi[INVESTIGATOR_532540] -titration is outlined in 
Section [IP_ADDRESS] . If subjects meet  up-titration criteria, a bottle of glimepi[INVESTIGATOR_14956], 4 mg, 6 mg 
or placebo, will be dispensed. If subjects do not meet up -titration criteria, subjects will 
continue the glimepi[INVESTIGATOR_532561]. The  up-titration  of 
glimepi[INVESTIGATOR_532562] g can occur before the scheduled study visits in the case of persistent 
hyperglycemia.  
 
Weeks 7 to 96 
• From weeks [ADDRESS_691504] will continue taking glimepi[INVESTIGATOR_532563] 6.  
• At week [ADDRESS_691505] will receive 
1 bottle of glimepi[INVESTIGATOR_532501], 2mg, 4 mg, 6 mg or placebo, based on the kit number 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 46 of 79 Version 3.0  (Global ) assigned to the subject by [CONTACT_8784]. At visit V15, two bottles of glimepi[INVESTIGATOR_532564] 72 and week 96 .  
 
6.14 Adverse Events Assessments  
6.14.1  Definition of Adverse Events  
Adverse event (AE ): Any untoward medical occurrence in a subject administered a 
pharmaceutical product that does not necessarily have a causal relationship with the 
treatment.  
An AE can t herefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not it is considered related to the medicinal product use.  
Serious adverse  event (SAE): A serious adverse event (experience) or reaction is any 
untoward medical occurrence that at any dose:  
1. results in death,  
2. is life -threatening,  (NOTE: The term "life -threatening" in this context refers to an event 
in which the subject was at r isk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it were more severe.)  
3. requires inpatient hospi[INVESTIGATOR_1081],  
4. results in persistent or significant  disability/incapacity,  
5. is a congenital anomaly/birth defect, or  
6. is a medically important event or reaction.  Medical and scientific judgment should be 
exercised in deciding whether other situations should be considered serious such as 
important medical ev ents that might not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_532565]. These should also usually be 
considere d serious.  Examples of such events are intensive treatment in an emergency 
room or at home for allergic bronchospasm , blood dyscrasias or convulsions that do not 
result in hospi[INVESTIGATOR_059] , or development of drug dependency or drug abuse.  
 
Adverse Reaction : An adverse reaction means any adverse event caused by a drug. Adverse 
reactions are a subset of all suspected adverse events in which there is a reason to conclude 
that the drug caused the event.  
Unexpected Adverse Drug Reaction (UADR): An adverse reacti on, the nature or severity 
of which is not consistent with the applicable product information ( see the Investigator’s 
Brochure for an unapproved investigational medicinal product).  
Serious and Unexpected Suspected Adverse Reaction (S[LOCATION_003]R): The sponsor must  report 
in an Investigational New Drug ( IND) safety report any suspected adverse reaction to study 
treatment (including active comparators) that is both serious and unexpected (21 CFR 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 47 of 79 Version 3.0  (Global ) 312.32(c)(1)(i)). Before submitting an IND safety report, the sponsor ne eds to ensure that the 
event meets all three of the definitions:  
• Suspected adverse reaction  
• Serious  
• Unexpected  
 
Severity: AEs will be graded on a 3 -point scale and reported as indicated in the CRF. The 
intensity of an adverse experience is defined as f ollows:  
1 = Mild: event is medically significant but produces no disruption to daily activity ; 
2 = Moderate: event is medically significant and reduces or affects normal daily activity;  
3 = Severe: event is medically significant and results in inability to  work or perform normal 
daily activity.  
Investigational Product Causality: An assignment will be made by [CONTACT_532596]. Cases with causal relationship classified as 
possible, probable or definite are defined as related. Cases with causal relationship 
categorized as not likely or unrelated are defined as not related. Relationship  of an AE to 
dosing will be assessed as follows:  
Definite:  The event responds to withdrawal of the investigational product  (dechallenge), 
and recurs with rechallenge by [CONTACT_272263].  
Probable:  There is a reasonable causal relationship between the investigational product 
and the AE. The event responds to dechallenge. Rechallenge is not required . 
Possible:  There is a reasonable causal relationship between the investigational product 
and the AE. Dechallenge is lacking or dechallenge response is unclear.  
Not Likely : There is a temporal relationship to investigational product administration, 
but the re is not a reasonable causal relationship between the investigational product and 
the event.  
Unrelated:  There is not a temporal or causal relationship to investigational product 
administration.  
6.14.[ADDRESS_691506] consents to participation in the study. To avoid bias in collecting information about 
AEs, the investigator should ask subjects the following question: "How have you felt since 
you were las t checked?" All AEs (serious and non -serious) reported by [CONTACT_532597].  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 48 of 79 Version 3.0  (Global ) It is the investigators responsibility to review the results of all laboratory tests as they 
become available. For each abnormal laboratory test result the investigator needs to ascertain 
if the result is a clinically significant change from baseline for that individual subject . This 
determination, however, does not necessarily need to be made the first time an abn ormal 
value is observed. The investigator may repeat the laboratory test or request additional tests 
to verify the results of the original laboratory tests. If the laboratory value is determined to be 
a clinically significant and an abnormal change from ba seline for that subject, th e result  is 
considered a laboratory AE.  
Hypoglycemia is defined as any FPG or SMBG value ≤ 70 mg/dL and documented as 
described in Section 6.14.11 . 
Any increase in liver function tes ts (AST, ALT, or bilirubin) greater than [ADDRESS_691507] values that fall below this threshold may be considered 
clinically significant and entered as an AE if the change is determined to be clinically 
significant.  
In addition, the sponsor ’s Medical Monitor or its designated personnel must be n otified 
immediately by [CONTACT_756], email, or fax of any immediately reportable AEs (IRAE) 
according to the procedure outlined below. Special attention should be paid to recording 
hospi[INVESTIGATOR_34910].  
6.14.[ADDRESS_691508] (including 
laboratory abnormalities) should be reported to the sponsor within [ADDRESS_691509] review guidelines abou t 
study participation for WOCBP. The topi[INVESTIGATOR_78609]:  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 49 of 79 Version 3.0  (Global ) • General information  
• Informed consent form  
• Pregnancy prevention information  
• Drug interactio ns with hormonal contraceptives  
• Contraceptives in curre nt use  
• Guidelines for the fo llow-up of a reported pregnancy  
 
Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy. The 
subject must sign an informed consent form stating th e above -mentioned risk factors and that 
the consequences were discussed with her.  
During the study, all WOCBP should be instructed to contact [CONTACT_397924] ( e.g., missed or late menstrual cycle).  
If a s ubject or investigator suspects that the subject may be pregnant prior to investigational 
product administration, the investigational product administration must be withheld until the 
results of serum pregnancy tests are available. If the pregnancy is conf irmed, the subject must 
not receive the investigational product and must not be enrolled or remain in the study. If 
pregnancy is suspected while the subject is receiving study treatment, the investigational 
product must be withheld immediately until the re sult of the pregnancy test is known. If 
pregnancy is confirmed, the investigational product will be permanently discontinued and the 
subject will be withdrawn from the trial. (Exceptions to study discontinuation may be 
considered for life -threatening condi tions only after consultations with the sponsor Medical 
Monitor or designated personnel.) The investigator must notify the Medical Monitor within [ADDRESS_691510] it to 
sponsor’s Medical Monitor or designated personnel.  
Protocol -required procedures for study discontinuation and follow -up must be performed on 
the subject unless contraindicated by [CONTACT_8663] ( e.g., x-ray studies). Other appropriate 
pregnancy follow -up procedures should be considered if indicated. In addition, the 
investigator must report to the sponsor, on the appro priate Pregnancy Surveillance Form, 
follow -up information regarding the course of the pregnancy, including perinatal and 
neonatal outcome. Infants will be followed for a minimum of six months.  
6.14.[ADDRESS_691511]’s treatment is required for clinical care and safety. The Emergency Code Break 
module in the IWRS is used for such situations. The investigator must confirm the intention 
to unblind the subject’s treatment to obtain the dose information in IWRS. Upon completion 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 50 of 79 Version 3.0  (Global ) of the unblinding, the system will send an alert to designated study team members that an 
unblinding event has occurred. Documentation of break ing the blind should be recorded in 
the subject’s medical record with the date and time the blind was broken, and the names of 
the personnel requesting and authorizing unblinding. The treatment assignment will continue 
to be withheld from the CEC members.  
6.14.[ADDRESS_691512]’s condition. The 
investigator should continue to report any significant follow -up information to the sponsor 
until the event has been resolved.  
Any new SAEs repor ted by [CONTACT_397926], and are determined by [CONTACT_272268], should be reported to the sponsor or designated personnel. T his 
may include SAEs that are captured on follow -up telephone contact [CONTACT_397927] ( i.e., up to last scheduled contact). The investigator should 
follow SAEs identified after the last scheduled contact [INVESTIGATOR_201170], or the 
subject is lost to follow -up. The investigator should continue to report any significant follow -
up information to the sponsor until the event has been resolved. This study requires that 
subjects be actively monitored for SAEs fo r at least [ADDRESS_691513] Infections (UTIs)  
Events potentially representing UTIs, including cystitis, urethritis, pyelonephritis, or 
urosepsis, should be carefully evaluated and documentation of signs, symptoms, culture 
results for infectious agent, and treatment should be undertaken when appropriate.  
The investigator should query the subject at every clinical visit for symptoms that may be 
related to a UTI and, if appropriate, document these events as symptomatic UTI in t he CRF 
unless an alternative diagnosis is present. In addition, a clean catch urine sample will be 
obtained at all clinical visits and a urinalysis will be performed on that sample at every 
clinical visit. A positive urinalysis will be defined as one with detectable leukocyte esterase 
and/or nitrites. If the subject reports symptoms consistent with a UTI or the urinalysis at the 
clinical site is positive, a urine culture will be performed at the central laboratory. A positive 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 51 of 79 Version 3.0  (Global ) urine culture will be defined a s one with ≥ 105 CFU of any species. The investigator may 
also perform a urine culture using local resources if necessary for clinical care.  
6.14.9  Genital Mycotic Infections (GMIs)  
The investigator will query the subjects for signs or symptoms that may represen t a GMI at 
all clinic visits. GMIs will be diagnosed based on symptoms and, if appropriate, physical 
exam and laboratory findings. Investigators must exclude the possibility of sexually 
transmitted infections before diagnosing GMI. Diagnosis of GMIs must b e documented in 
the CRF.  
6.14.[ADDRESS_691514] and/or ALT concentrations > [ADDRESS_691515] within the 14 days of the detected abnormality; and any symptoms or 
change in physical exam that have occurred since the prior assessment. The investigator 
should perform additional laboratory  and imaging tests to attempt to establish the cause of 
the AST and ALT elevations, including ruling out any potential contribution from bone or 
muscle etiologies.  
Any clinically significant increase in hepatic enzymes and specifically any ALT or AST > [ADDRESS_691516] every 96 h (4 days) 
until ALT and AST return to < 2.[ADDRESS_691517]. Study medication should be stopped an d the event 
should be reported as a laboratory AE within the CRF if the enzyme elevation is confirmed 
or worsening.  
Hepatotoxicity will be diagnosed and entered as an AE should any of the following occur:  
• ALT or AST > [ADDRESS_691518]  
• ALT or AST > [ADDRESS_691519] and tota l bilirubin > [ADDRESS_691520] or INR > 1.5  
• ALT or AST > [ADDRESS_691521] with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).  
 
In the event of hepatotoxicity, investigational product should be d iscontinued. If no 
alternative cause of hepatotoxicity to the study drug is identified, the study drug should not 
be restarted. If an alternative cause of hepatotoxicity is identified, study drug administration 
may be resumed after the liver function testi ng returns to baseline and any related symptoms 
have resolved. If the liver function abnormalities or related symptoms recur after dosing is 
resumed, the study drug dosing should be permanently discontinued.  The investigator is 
encouraged to consult with the Medical Monitor regarding diagnostic evaluation for the 
hepatic enzyme elevations. Consultation with a hepatologist may also be appropriate in some 
circumstances.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 52 of 79 Version 3.0  (Global ) 6.14.[ADDRESS_691522] in the glycemic control diary the following 
information for each hypoglycemic event:  
1. Signs and symptoms attributed to hypoglycemia and the time and date on which they 
occurred  
2. SMBG reading at the time of the signs and symptoms attribu ted to hypoglycemia  
3. Time elapsed from the most recent meal to the onset of signs and symptoms  
4. Duration, intensity, and type of any exercise within the 24 h prior to the signs and 
symptoms  
5. Type of treatment used ( e.g., juice, crackers) for the signs and sym ptoms and whether 
assistance was required from another person to administer the treatment  
6. SMBG reading 15 minutes after treatment with carbohydrate and the time at which 
this was measured  
7. Whether or not the signs and symptoms attributed to hypoglycemia res olved after 
blood glucose returned to normal.  
 
Subjects are encouraged to call the study clinic should signs and symptoms potentially 
related to hypoglycemia occur.  
At each study visit, the investigator is expected to review the glucometer and glycemic 
control diary with particular attention to any SMBG value ≤ 70 mg/dL and any recorded 
signs or symptoms potentially related to hypoglycemia. In addition, the investigator should 
query the subject with regard to the occurrence of signs and symptoms potentially  related to 
hypoglycemia even if none are recorded in the diary.  
In the event of a blood glucose value ≤ 70 mg/dL or signs and symptoms potentially related 
to hypoglycemia, the investigator should complete the supplemental CRF which will include 
data from  the glycemic control diary and action items to reduce future hypoglycemia 
epi[INVESTIGATOR_1841].  
Hypoglycemia events will be recorded in the hypoglycemia log under 5 categories:  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 53 of 79 Version 3.0  (Global ) 1. Severe hypoglycemia: an event requiring assistance by [CONTACT_532598], glucagon, or other resuscitative actions. These epi[INVESTIGATOR_272210]. Plasma glucose 
measurements may not be available during such an event, but neurological recovery 
attribut able to the restoration of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration. All such 
events should be recorded as SAEs in the CRF.  
2. Documented symptomatic hypoglycemia: an event dur ing which typi[INVESTIGATOR_272211] a measured plasma glucose concentration ≤ 70 mg/dL 
(3.9 mmol/L).  
3. Asymptomatic hypoglycemia: an event not accompanied by [CONTACT_11017][INVESTIGATOR_78237] a measured blood glucose concentration ≤70 mg/dL 
(3.9 mmol/L).  
4. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia 
are not accompanied by a blood glucose determination but that is presumably caused by a 
blood glucose concentration ≤ 70 mg/dL (3.9 mmol/L).  
5. Relative hypoglycemia: An event during which the person with diabetes reports any of 
the typi[INVESTIGATOR_532566], and interprets those as indicative of 
hypoglycemia, but with a measured  plasma glucose concentration >  70 mg/dL 
(3.9 mmol/L).  
 
While each event meeting the criteria above will be entered into the hypoglycemia log, only 
critical hypogly cemia, documented symptomatic hypoglycemia, asymptomatic 
hypoglycemia, and probable hypoglycemia will be entered as AEs.  
In the event of asymptomatic hypoglycemia, the investigator should review the signs and 
symptoms of hypoglycemia with the subject to e licit a complete description and should 
review proper glucometer technique to ensure that the low glucose value is not due to 
improper use of the glucometer.  
The investigator should be alerted to the likelihood of improper glucose measurement 
technique if a study subject reports an SMBG value <  55 mg/dL that is not associated with 
any signs or symptoms of hypoglycemia and is not treated by [CONTACT_397929].  
In the event of probable symptomatic hypoglycemia, the investigator should encour age the 
subject to obtain glucose values, when possible, in the context of signs and symptoms of 
hypoglycemia, even if the glucose value is measured after treatment for the symptoms is 
administered.  
If hypoglycemia occurs in any subject prescribed rescue m edication for hyperglycemia 
during the study, the total daily dose of the rescue medication should be reduced 50% or 
more at the discretion of the investigator.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 54 of 79 Version 3.0  (Global ) 6.14.12  Diabetic Ketoacidosis (DKA)  
DKA is a serious, acute complication of diabetes and can be life -threatening . Subjects will be 
educated on the signs and symptoms of DKA and are required to call the study clinic and 
seek treatment should such signs and symptoms occur.  
During the clinical trial period, potential DKA will be monitored by [CONTACT_532599]. 
Clinical presentations, such as difficulty breathing, abdominal pain, nausea, vomiting, 
lethargy, or a fruity smell in the breath, or laboratory values that su ggest clinically  significant 
acidosis should be documented . Treatment of DKA should be provided when appropriate.  
If ongoing symptoms or signs suggest a possible DKA, the investigator should perform 
relevant laboratory testing while directing appropriate medical care for the subject. If DKA is 
suspected, regardless of the blood glucose level, the following assessments should be done 
immediately: physical exam and serum glucose, bicarbonate, electrolytes, and serum ketones 
measured STAT at a local laborator y. If ketoacidosis is likely, investigational product 
administration should be discontinued and immediate appropriate medical therapy, including 
insulin, should be initiated . A glucose infusion may be provided if necessary to avoid 
hypoglycemia during insu lin therapy. Insulin treatment should continue until resolution of 
the ketoacidosis and stabilization of the subject’s clinical condition. Investigational product 
administration may be resumed following stabilization of the subject’s condition. 
Investigato r should collect the data necessary for the completion of the DKA CRF.  
If symptoms suggestive of DKA may have occurred but are not ongoing, investigator should 
review available data in order to complete the DKA CRF . The investigator may also perform 
labora tory assessment using local resources if necessary for clinical care.  
6.14.13  Major Adverse Cardiovascular Event (MACE)  
Evaluation of MACE will be undertaken across the development program for bexagliflozin. 
All MACE reports should also be captured as SAEs and eve ry effort will be made to ensure 
that events recorded as MACE are coded in a similar manner within the safety database. The 
SAE listing will also be reviewed periodically by [CONTACT_272272]. All subjects will be 
followed by [CONTACT_272273].  
The independent CEC will receive and adjudicate the following events.  
 All deaths  
 Suspected n on-fatal myocardial infarction (MI)  
 Suspected hospi[INVESTIGATOR_10929] (HUA)  
 Suspected transient ischemic attack (TIA) and stroke  
 Suspected hospi[INVESTIGATOR_19934] (HF)  
 Reported coronary revascularization procedure  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 55 of 79 Version 3.0  (Global )  
6.14.[ADDRESS_691523] be documented on the CRF. This 
documentation should continu e until the subjects complete the study.  
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO -DD). A table of concomitant medications based on the anatomic 
therapeutic chemical classification (ATC) and preferred n ame will be produced. A listing of 
concomitant medications will include all medications taken by [CONTACT_272274].  
6.16 Healthy -related Quality of Life Assessment  
EQ-5D-3L is a multi -attribute utility instrument  for measuring preferen ces associated with an 
individual’s health state. The instrument includes a visual analog scale and a descriptive 
system with 5 dimensions  (mobility, self -care, usual  activity, pain/discomfo rt, 
anxiety /depression), each of which has 3 levels (no problem, s ome problem, extreme 
problem) . 
Enrolled subjects will complete the EQ-5D-3L questionnaire independently at clinic Visits 
V6, V11, V14 and V17. EQ-5D-3L should be completed prior to other scheduled procedures 
at those visits.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 56 of 79 Version 3.0  (Global ) 6.[ADDRESS_691524] ( IRB)/Independent Ethics Committ ee (IEC) determines that, 
based on good medical judgment , immediate cessation is appropriate for subject safety. If a  
decision is made to withdraw a subject from the study, no further investigational product 
should be administered. Even if the subject disc ontinues study medication, every attempt 
should be made to complete all required study evaluations and procedures. Reasons for all 
withdrawals should be recorded on the CRF. Examples of reasons for withdrawal include:  
1. A protocol violation has occurred , 
2. A serious or intolerable adverse event has occurred , 
3. A clinically significant change in a laboratory parameter has occurred,  
4. The sponsor or investigator terminates the study, or  
5. The patient requests to be withdrawn  from the study.  
 
Subjects who do not complet e the study but who have received investigational product 
should have a follow -up examination, including a physical examination, vital signs, ECG and 
clinical laboratory tests according to  Section 7.6 . 
Subjects who withdraw from the study will not be replaced.  
6.18 Appropriateness of Measurements  
The percentage of HbA1c is a widely used measure of chronic glycemia, reflecting average 
blood glucose levels over a 2 - to 3-month period of time. It is an accept ed surrogate marker 
of risk of microvascular complications and is widely used as a measurement for the adequacy 
of glycemic management. Other study procedures and measurements in this protocol are 
widely used and generally recognized as reliable, accurate,  and relevant for subjects with 
T2DM.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 57 of 79 Version 3.0  (Global ) 7 STUDY ACTIVITIES  
The study activities at each clinic visit listed below are presented in Appendix 1.  The 
required laboratory tests scheduled at each visit are listed in Appendix 2 . Detailed study 
procedures are described in Section 6 .  
A visit window of ± 3 days is allowed for all visits except Visit V6. Visit V6 is the day of 
randomization and is the basis for all subseq uent visit window s.  
7.1 Screening Period  
7.1.1  Visit V1 (3 days to 3 weeks for metformin -only group and u p to 9 weeks for 
metformin -and-OHA group  before run -in period ) 
The screening can be performed from 3 days to 3 weeks  before the start of the wash -out 
period for  subjects who are metformin -and-OHA treated and 3 days to 3 weeks  before the 
start of the run -in period for subjects who are metformin -only treated . At the screening visit, 
the staff at the investigational site will:  
• Explain the content of the informed con sent materials to the subject and collect signed 
informed consent  
• Evaluate inclusion and exclusion criteria based on the information collected at the 
screening visit. Verify compliant fasting st atus as described in Section 6.9 .2.1. 
• Obtain medical history and demographic information  
• Perform an abbreviated physical examination  and record body weight and height  
• Measure vital signs, including blood pressures and heart rate  
• Perform a 12 -lead ECG measurement  
• Draw blood i f a minimum [ADDRESS_691525] as described in 
Section 6.9 .2.1. The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a c lean-catch, mid -stream urine sample  
 
7.2 Wash -out and Run -in Period (Up to 8 weeks prior to 
randomization ) 
The wash -out and run -in period is required for any enrolled subject who is taking metformin 
and one additional OHA . Eligible subjects  who are taking metf ormin only  will enter the run -
in period  directly . 
7.2.1  Wash -out Period  (Visits V2 and V3) 
Two visits will be conducted during the wash -out period . V2 is an on -site clinic visit. At V3 
each subject will be evaluated by [CONTACT_532600] a phone  interview . 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 58 of 79 Version 3.0  (Global ) [IP_ADDRESS]  Visit V2 (8 weeks prior to randomization)  
• Evaluate inclusion and exclusion criteria based on the information collected at the 
screening visit. Verify compliant fasting st atus as described in Section 6.9 .2.1. 
• Counsel subject on appropriate diet and exercise  (for subjects who are metformin -and-
OHA  treated ) 
• Dispense glucometer and instruct subject in SMBG determination and recording  (for 
subjects who are metformin -and-OHA treated)  
• Start wash -out and d iscon tinue the non -metformin OHA  
• Assess adverse events and potential DKA  
• Record pre -treatment medications  
 
[IP_ADDRESS]  Visit V 3 (6 weeks prior to randomization , off-site phone visit ) 
• Review SMBG and glycemic control record  
• Assess adverse events and potential DKA  
• Record pr e-treatment medications  
 
7.2.2  Run-in Period  
[IP_ADDRESS]  Visit V 4 (2 weeks prior to randomization ) 
• Counsel subject on appropriate diet and exercise  (for subjects who receive metformin 
only and do not need a washout)  
• Dispense glucometer and instruct subject in SMBG determin ation and recording (for 
subjects who receive metformin -only)  
• Review SMBG and glycemic control record (for subjects who receive metformin + 1 
OHA)  
• Dispense run -in kits for run -in period  
• Measure vital signs, including blood pressures and heart rate  
• Assess a dverse events and potential DKA  
• Record pre -treatment medications  
 
[IP_ADDRESS]  Visit V 5 (3 to 5 days prior to randomization ) 
• Evaluate inclusion and exclusion criteria based on the information collected at the 
screening visit. Verify compliant fasting st atus as describe d in Section [IP_ADDRESS] . 
• Perform a complete physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Perform a 12 -lead ECG meas urement  
• Draw blood if a minimum [ADDRESS_691526] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appe ndix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record pre -treatment medications  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 59 of 79 Version 3.0  (Global )  
7.3 Treatment Period (Day 1 to Week 96) 
At the end of the run -in period, subjects who have successfully completed run -in period an d 
continue to meet the inclusion/exclusion criteria will be randomized and enter the treatment 
period.  
7.3.1  Visit V6 (Day 1 of Week 1)  
Visit V6, day of randomization, must be conducted after the HbA1c value from the sample of 
Visit V5 is available for eligibili ty confirmation.  
• Complete EQ -5D-3L  questionnaire  
• Review SMBG and glycemic control record  
• Collect used run -in medications and d ispense investigational products  based on 
randomization  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.3.2  Visit V 7 (Week 2) 
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medication, if  applicable,  and d ispense glimepi[INVESTIGATOR_532567]-
titration criteria assessment  
• Assess adverse events  and potential DKA  
• Record concomitant medications  
 
7.3.3  Visit V 8 (Week 4) 
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medication, if  applicable,  and dispense glimepi[INVESTIGATOR_532568] -
titration criteria assessment  
• Assess adverse events and potential DKA  
• Record  concomitant medications  
 
7.3.4  Visit V 9 (Week 6) 
• Perform an abbreviated  physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, includin g blood pressures and heart rate  
• Collect used study medication, if  applicable, and d ispense glimepi[INVESTIGATOR_532568] -
titration criteria assessment  
• Draw blood if a minimum [ADDRESS_691527] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 60 of 79 Version 3.0  (Global ) • Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record concomitant me dications  
 
7.3.5  Visit V 10 (Week 1 2) 
• Review SMBG and glycemic control record  
• Record body weight  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medications and d ispense investigational products  
• Draw blood if a minimum [ADDRESS_691528] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream  urine sample  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.3.6  Visit V 11 (Week 24)  
• Complete EQ -5D-3L questionnaire  
• Perform an abbreviated  physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vi tal signs, including blood pressures and heart rate  
• Perform a 12 -lead ECG measurement  
• Collect used study medications and d ispense investigational product s  
• Draw blood if a minimum [ADDRESS_691529] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record  conc omitant medications  
 
7.3.7  Visit V 12 (Week 36)  
• Perform an abbreviated  physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medications and d ispense in vestigational product s  
• Draw blood if a minimum [ADDRESS_691530] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 61 of 79 Version 3.0  (Global ) 7.3.8  Visit V 13 (Week 48) 
• Perform a n abbreviated  examination  and record body weight  
• Review SMBG and glycemic control r ecord  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medications and d ispense investigational product s 
• Draw blood if a minimum [ADDRESS_691531] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.3.9  Visit V14 (week  60) 
• Complete EQ -5D-3L questionnaire  
• Perform a complete physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Perform a 12 -lead ECG measurement  
• Collect used study medications and d ispense investigational product s  
• Draw blood if a minimum [ADDRESS_691532] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for t his visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.3.10  Visit V15 (week 72 ) 
• Perform an abbreviated  physical examination  and r ecord body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Collect used study medications and d ispense investigational product s  
• Draw blood if a minimum [ADDRESS_691533] has been completed by [CONTACT_70579] t as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample  
• Assess adverse eve nts and potential  DKA  
• Record concomitant medications  
 
7.3.11  Visit V16 (week 84 , off-site phone visit ) 
• Review SMBG and glycemic control record  
• Assess adverse events and potential DKA  
• Record concomitant medications  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 62 of 79 Version 3.0  (Global )  
7.3.12  Visit V17 (end of treatment, week 96 ) 
• Complete E Q-5D-3L questionnaire  
• Perform an abbreviated physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Perform a 12 -lead ECG measurement  
• Draw blood if a minimum [ADDRESS_691534] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream urine sample.  
• Collect used investigational products  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.4 Visit V18 ( Exit Visit or Early Termination Visit ) 
7.4.1  Visit V18  (week [ADDRESS_691535] withdraws consent ) 
• Perform a complete physical examination  and record body weight  
• Review SMBG and glycemic control record  
• Measure vital signs, including blood pressures and heart rate  
• Draw blood if a minimum [ADDRESS_691536] as described in 
Section [IP_ADDRESS] . The specific laboratory tests scheduled for this visit are listed in 
Appendix 2 . 
• Collect a clean -catch, mid -stream uri ne sample  
• Collect used investigational products  if early termination  
• Assess adverse events and potential DKA  
• Record concomitant medications  
 
7.[ADDRESS_691537] adm inistration early but are willing to 
remain in the study to allow safety information to be collected should complete the End of 
Treatment visit procedures. Safety data may be documented following the scheduled clinic 
visit and/or phone interview procedures  as much as possible without the study drug 
dispensation and accountability procedures. Alternative follow -up methods to allow safety 
assessment to be recorded may be implemented as unscheduled visits.  
7.[ADDRESS_691538] a 
follow -up examination, including a complete physical examination, vital signs, ECG, and 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 63 of 79 Version 3.0  (Global ) clinical laboratory tests (hematology, serum chemistry, and glycemic control). The sponsor 
must be notifie d in the event that a subject withdraws or has been withdrawn from the study.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 64 of 79 Version 3.0  (Global ) [ADDRESS_691539] Oper ating Procedures ( SOPs ) of the contract research organization 
(CRO ) and the sponsor. Review procedures will be implemented at the CRO for all 
documents that are generated in relation to the study.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 65 of 79 Version 3.0  (Global ) 9 PLANNED STATISTICAL METHODS  
9.1 General Considerations  
The foll owing sections provide a summary of the planned analysis of the trial but a complete 
statistical analysis plan will be developed as a separate document and will be the final plan. 
All statistical analyses will be performed using SAS Version 9.2 or higher.  
In general, descriptive statistics (number of subjects [N], mean, standard deviation [SD], Q1, 
median, Q3, minimum and maximum) will be presented for continuous variables, and 
frequency and percentage for categorical variables.  
The primary efficacy non -inferiority test will be one -sided at 0.025 significance level. The 
upper bound of the 95% confidence interval (CI) on the difference of HbA1c reduction 
between bexagliflozin and glimepi[INVESTIGATOR_532569]’s conclusion. That 
is, if the u pper bound of the CI is within 0.35%, then the primary objective of the study is 
met.  Superiority will be declared without additional statistical testing when the upper bound 
of the 95% CI for the difference in change from baseline at week 60 in HbA1c comp aring 
bexagliflozin group with glimepi[INVESTIGATOR_532570] 0.  
The secondary efficacy objectives will be tested at two -sided 0.05 significance level 
following a sequential testing procedure to control the overall type I error of 0.05. The 
secondary effi cacy endpoints will be tested only if the primary efficacy assessment achieves 
significance, and following the hierarchy as below:  
1. Superiority test of the change in body weight in subjects with baseline BMI ≥ 25 kg/m2 in 
the bex agliflozin group compared wi th glimepi[INVESTIGATOR_532571] [ADDRESS_691540] of the change in SBP in subjects with baseline SBP ≥[ADDRESS_691541] of the difference in   proportion of subjects with ≥ [ADDRESS_691542] with a one -sided 
significance at the 0.025 level and the following assumptions:  
1. The non -inferiority limit (margin) for mean change from baseline to week 60 in HbA1c 
comparing bexagliflozin group to glimepi[INVESTIGATOR_532507] 0.35%  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 66 of 79 Version 3.0  (Global ) 2. The pooled standard deviation for the change f rom baseline to week 60 in HbA1c for 
bexagliflozin group and glimepi[INVESTIGATOR_532507] 1.0%  
 
Under the above assumptions, an estimated sample size of [ADDRESS_691543] with 90% 
power at a 0.025 level of significance. A sample size of 210 per arm has been selected to 
account for approximate 1 8% drop -out rate and to allow adequate safety evaluation. The total 
sample size for this study will be 420 subjects.  
This study will be conducted at multiple investigative sites and will likely involve various 
numbers of subjects at each site. Enrollment will be on a competitive basis,  but will be 
capped at 40 subjects from each site.  
9.3 Analysis Populations  
9.3.1  Intention -to-Treat Analysis set  
All subjects who are randomized regardless of treatment adherence or availability of follow -
up data will be included in the intention -to-treat analysis  set (ITT). All analyses of the ITT 
will be based on each subject’s randomized assigned treatment. The ITT analysis set will 
serve as the primary set for the efficacy analyses.  
9.3.[ADDRESS_691544].  The Safety Analysis Set is the primary analysis set 
for safety evaluation.  
9.3.3  Per Protocol Analysis Set  
The Per Protocol (PP) Analysis Set will include all subjects in the ITT who meet the study 
eligibility requirements and have no major protocol deviations that affect the validity of the 
efficacy measurements. Protocol deviations that may resul t in subject exclusion from the PP 
Analysis Set will be detailed in the Statistical Analysis Plan. The subject assignment to the 
PP analysis set will be determined prior to database lock. The PP analysis set will serve as 
the secondary set for efficacy ass essments.  
9.4 Demographics and Baseline Characteristics  
Demographic and baseline characteristics will be summarized descriptively based on the ITT 
and PP analysis set for each treatment group as well as for all subjects combined. Key 
variables include age, gen der, race, ethnicity, baseline HbA1c values, blood pressure, body 
weight, body mass index (BMI in kg/m2), fasting plasma glucose level, eGFR, duration of 
diabetes and prior anti -diabetic treatment status at screening (including type of therapy used 
[metfor min, sulfonylurea, DPP -4 inhibitor, alpha -glucosidase inhibitor etc.]). In general, 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 67 of 79 Version 3.0  (Global ) baseline measurement is defined as the last measurement prior to the first dose of double -
blind medication. 
9.4.1  Concomitant Medications  
Concomitant medications will be coded us ing the World Health Organization Drug Dictionary 
(WHO -DD), and include medications that are either started prior to the study treatment and 
continue to be taken during the study treatment period, or medications started after the start of 
study treatment. Concomitant medications will be summarized by [CONTACT_532601].  
9.5 Primary Efficacy Analyses  
9.5.1  Hypotheses for the Primary Endpoint  
The null and alternative hypotheses for the primary endpoint are:  
H0: µ bexagliflozin  - µ comparator  > δ 
Ha: µ bexagliflozin  - µ comparator  ≤ δ 
Where µ bexagliflozin  and  µ comparator  represent the mean change in HbA1c at week 60 from 
baseline for bexagliflozin and comparator groups, respectively. Non -inferiority margin δ is 
chosen to be 0.35% using clini cal judgment, with reference to relevant regulatory guidance.  
9.5.2  Statistical Methods for Primary Analyses  
For the primary endpoint, the treatment difference will be examined by [CONTACT_2329] a mixed model 
repeated measures (MMRM) analysis of covariance model (ANCOVA) . The model will 
include  treatment, visit, treatment -by-visit interaction and randomization stratification factors 
as the fixed effects terms and the baseline HbA1c value as a fixed effect covariate. Least 
squares mean treatment differences between the bex agliflozin group and the comparator 
group at week [ADDRESS_691545] correlation. If the model with the unstructured covariance 
structure does not converge, an autoregres sive(1) covariance structure will be used.  
HbA1c values obtained after the start of rescue medication will not be excluded in the 
analysis. These analyses will be conducted on both ITT (primary) and PP analysis sets, and 
conclusions can be considered more  robust when both approaches support the non -inferiority 
of the treatment.  
In non -inferiority analysis, a CI is calculated to estimate the range of values in which the  
treatment difference  is likely to lie. This CI is used to provide the basis for drawing the 
study’s conclusions.  In this specific test, if the 95% CI lies below the specified non -
inferiority margin 0.35%, the results would lead to a conclusion of non -inferiority of 
bexagliflozin treatment to glimepi[INVESTIGATOR_532572]. Superiority of bexagliflozin  group over 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 68 of 79 Version 3.0  (Global ) glimepi[INVESTIGATOR_532571] 60 in HbA1c change from baseline will be declared if the upper 
bound  of 95% CI is less than 0.  
Sensitivity analyses will also be performed as the following, and these analyses will be 
conducted for ITT and PP analysis  sets. 
1. Missing data will be imputed via multiple imputations, following which the MMRM will 
be repeated on the complete datasets with results combined across complete datasets 
using standard MI techniques; HbA1c values collected after the start of rescue m edication 
will not be excluded.  
2. Missing data will be imputed via LOCF, following which the MMRM will be repeated; 
HbA1c values collected after the start of rescue medication will be considered missing.  
3. HbA1c values collected after the start of rescue medic ation will be considered missing, 
and the MMRM analyses will be re -performed.  
 
9.5.3  Analysis of Dropouts Pattern  
The early termination rate is estimated to be 18%. To the extent possible, attempts will be 
made to minimize the amount of missing data through meas ures planned in the study 
conduct.  
The number, timing, pattern, reason for and possible implications of missing values in 
efficacy assessments will be investigated. The dropout patterns will be assessed by [CONTACT_5263] -
Meier plots if applicable to assess whether  they differ between treatment groups.  
9.[ADDRESS_691546] on the change of body weight in subjects with baseline BMI ≥ 
25 kg/m2 at week 60, an analysis of covariance model (ANCOVA) will be implemented 
using all avail able data at week 60 (values obtained after the start of rescue medication will 
not be excluded in the analysis) . The model will include  treatment, randomization 
stratification factors, and the baseline weight value as fixed effects/covariates. Least squar es 
mean treatment differences between the bexagliflozin group and the comparator group will 
be estimated from the model. The corresponding 95% CI and p -value will be provided.  
The change in systolic blood pressure (SBP) in subjects with baseline SBP ≥ 140 mmHg in 
the bexagliflozin group compared with glimepi[INVESTIGATOR_532571] 60 will be analyzed using 
the same method.  
The difference in proportion of subjects with ≥ 1 severe or docum ented symptomatic 
hypoglycemia event s in the bexagliflozin group compared with glimepi[INVESTIGATOR_532573] 96 
weeks  will be analyzed using logistic regression model which includes  terms of treatment, 
randomization stratification. Odd ratio estimates, 95% two -sided confidence intervals and p -
values for the treatment difference will be provided.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 69 of 79 Version 3.0  (Global ) All analyses will be conducted in ITT analysis set. A hierarchical testing procedure will be 
applied to above three endpoints in the sequence provided above.  
9.7 Other Efficac y Analyses  
Changes in FPG, SBP/DBP, and body weight for all subjects during the treatment period will be 
summarized descriptively by [CONTACT_64200] (i.e., Weeks 2, 4, 6, 12, 24, …, etc.). In addition, 
these endpoints may be analyzed using a similar MMRM m odel as used for the primary analysis 
of HbA1c to compare two treatment groups.  
Cumulative summary on the proportion of subjects  achieving  HbA1c  < 7%, and the proportion of 
subjects with documented hypoglycemia event will be presented over time. Generaliz ed 
estimation equation (GEE) method may be utilized for assessment of treatment effects.  
Analyses will be conducted using ITT analysis set.  
9.8 Analysis of Safety  
Safety data include AEs, physical exam results, vital signs, ECG results, and clinical lab result s 
including serum chemistry, hematology, serum lipi[INVESTIGATOR_805], glycemic control parameters and 
urinalysis. Observed data will be summarized by [CONTACT_532602].  
9.8.1  Adverse Events  
AEs will be mapped to preferred term and body system using the Medic al Dictionary for 
Regulatory Activities (MedDRA) dictionary. AEs that begin at or after the first 
administration of double -blind study medication or existing AEs that worsen in severity after 
the first dose of double -blind study medication are considered t reatment emergent AEs 
(TEAE). The number and percentage of subjects reporting TEAEs will be summarized for 
each treatment group by [CONTACT_14340]. Further summaries 
by [CONTACT_926], and by [CONTACT_532603]. Drug -related 
adverse events will be considered those to be at least possibly related to the study treatments 
based on the investigators assessment.  
The number and percentage of subjects reporting serious AEs, and the number and 
percentage of  subjects reporting AEs leading to treatment discontinuation will also be 
summarized for each treatment group by [CONTACT_14340].  
9.8.[ADDRESS_691547] will be confirmed in a peer review 
process.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 70 of 79 Version 3.0  (Global ) The number and perce ntage of subjects experienced TEAE of special interest will be 
summarized for each treatment group by [CONTACT_532604]. The incidence rate of adverse 
events of special interest per 100 patient years will also be summarized. Additional analyses 
will be speci fied in the statistical analysis plan to evaluate other event associated safety 
parameters and potential risks in subpopulations based on age, gender, or other baseline 
characteristics . 
9.8.3  Clinical and Laboratory Events and Analyses  
Clinical laboratory (see Section [ADDRESS_691548]), vital signs, and 12 -lead ECG will be 
measured at scheduled visits (see Appendix 1 ). These data will be summarized as actual 
values and changes from baseline by [CONTACT_532605].  
Laboratory data will be classified as low, normal or high relative to the parameter’s reference 
range. Laboratory abnormalities for each treatment will also be summarized with shift tables 
for selected parameters.  
9.8.[ADDRESS_691549] using MMRM method. 
Similar to efficacy endpoints, the model will include  treatment, visit, treatment -by-visit 
interaction and randomization stratification factors as the fixed effects terms and the baseline 
EQ-5D-3L index score (or visual analog score) as a fixed effect covariate.  
9.[ADDRESS_691550] completed the planned 60 weeks of blinded study treatme nt and the 
subsequent safety extension and follow -up periods, the final analysis of the clinical study will be 
completed. At this time, the database will be cleaned and locked, and the treatment codes will be 
unblinded.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 71 of 79 Version 3.0  (Global ) [ADDRESS_691551] details of participating investigators, monitors, clinical laboratories, and technical 
departments and/or insti tutions, as well as information on members of additional study 
committees, will be found in the study files of the investigational site.  
10.[ADDRESS_691552]  (IRB) or Independent Ethics Committee 
(IEC) Approval  
The study protocol, informed consent do cument, relevant supporting information, and all 
types of subject recruitment or advertisement information must be submitted to the IRB/IEC 
for review and must be approved by [CONTACT_135785]/IEC before the study is 
initiated . Any amendments or adde nda to the protocol must also be approved by [CONTACT_1201]/IEC 
prior to implementing changes in the study . The investigator is responsible for keepi[INVESTIGATOR_230649]/IEC informed of the progress of the study and of any changes made to the protocol as 
deemed appropriate , but in any case at least once a year . The investigator must also keep the 
IRB/IEC informed of any SAEs occurring to subjects under their supervision.  
10.[ADDRESS_691553], evaluati on, and 
documentation of this study are designed to ensure that the sponsor and investigator follow 
ICH Good Clinical Practice (GCP) Guidelines and the guiding principles detailed in the 
Declaration of Helsinki. The study will also be carried out in keepin g with applicable local 
laws and regulations . An inspection by [CONTACT_142081]/or their designee 
and/or other authorized regulatory authorities representatives may occur at any time . The 
investigator must agree to the inspection of study -related records by [CONTACT_128920]/sponsor representatives, and must allow direct access to source documents to the 
regulatory authority/sponsor representatives.  
The investigator is responsible for complying with the protocol and all appropriate 
regulations and guidelines governing global clinical research . Additionally, he/she is 
responsible for ensuring that all participating staff members are adequately trained and 
competent to perform his/her assigned tasks.  
Modifications to the study protocol wi ll not be implemented by [CONTACT_23664] . However, the investigator may implement a 
deviation from or a change of the protocol to eliminate any immediate hazards to the trial 
subjects without prior I RB/IEC or sponsor approval/favorable opi[INVESTIGATOR_1649] . As soon as possible, 
the implemented deviation or change, the reasons for it, and if appropriate, the proposed 
protocol amendment should be submitted to the IRB/IEC  and sponsor.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 72 of 79 Version 3.0  (Global ) Any deviations from the protocol  must be fully explained and documented by [CONTACT_1275]. The circumstances, action taken, and impact of the deviation on the trial must be 
communicated by [CONTACT_458] [INVESTIGATOR_532574] . Any 
subsequent actions will be asse ssed by [CONTACT_532606].  
10.[ADDRESS_691554] received from the IEC or IRB 
the written approval or favorable opi[INVESTIGATOR_272215] -consent form and a ny other written 
information to be provided to subjects . The written approval of the IRB/IEC together with 
the approved subject information/ informed consent forms must be filed . The informed 
consent form must contain all elements required by [CONTACT_532607] (E6), in addition to, any other elements required by [CONTACT_397942].  
Written informed consent must be obtained before any study -specific procedure takes place . 
Participation in the study and date of informed consent given by [CONTACT_272286]’s files . A copy of the signed informed consent form 
must be provided to the subject . If applicable, it will be provided in a certified translation in 
the language understood by [CONTACT_423], if not English . Signed consent forms must remain in 
each subject’s study file and must be available for verification by [CONTACT_9534].  
10.[ADDRESS_691555]’s 
permission . To en sure compliance with current ICH guidelines, data generated by [CONTACT_272287], the sponsor, and the IRB/IEC for each study site . Study information from th is 
protocol will be posted on clinicaltrials.gov and any local regulatory registry websites, as 
required by [CONTACT_5151].  
Subject names and other identifiers, such as photographs, audio, or videotapes, may not be 
disclosed in any publication without prior wr itten authorization from the subject.  
10.[ADDRESS_691556] study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
national and local g overnment regulations and guidelines.  
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 73 of 79 Version 3.0  (Global ) The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and records rel evant to this study.  
10.[ADDRESS_691557] consented, a case report form (CRF), in paper or electronic format, will be 
supplied and maintained by [CONTACT_532608]/she has reviewed and agrees with the entered data . This also 
applies to those subjects who fail to complete the trial. The reason a subject is withdrawn 
must be recorded in the case report form.  
Entries made in the CRF must be verifiable against s ource documents. Source documents are 
defined as all medical records, medical notes, laboratory results, ECG traces and any 
additional document other than the CRF that has original subject information contained 
within it.  
All CRFs and source documents shou ld be completed following GCP and the Sponsor or its 
designees  standard operating procedures.  
10.[ADDRESS_691558] (DSMB) will monitor overall safety 
information during the bexagliflozin  development prog ram. The safety review activity and 
potential risk benefit assessments utilized by [CONTACT_532609].  
10.9 Protocol Violations/Deviations  
Protocol violations include deviations from the inclusion and exclusion criteria, concomitant 
medicat ion restrictions, and any other protocol requirement that results in a significant added 
risk to the patient or has an impact on the quality of the data collected or the outcome of the 
study. A deviation occurs when there is non -adherence to study procedur es or schedules, as 
specified by [CONTACT_760], which does not involve inclusion/exclusion criteria or the primary 
endpoint and which does not place the patient at any added risk or affect the data quality or 
study outcome. Examples of deviations may includ e common out -of-window visits, a missed 
procedure, etc. Protocol violations will reported in the final clinical study report, whereas 
protocol deviations may be mentioned but are not required to be reported.  
It is important to conduct the study according t o the protocol . Protocol deviation  waivers  will 
not be prospectively granted by [CONTACT_456] . If minor protocol deviations occur, the 
investigator must decide the most appropriate way to proceed with study activities and 
should consult the study representat ive for assistance. If major protocol deviations occur, the 
sponsor’s Medical M onitor must be notified immediately so that a decision about whether to 
keep the subject in the study can be made.  
Only when an emergency occurs that requires a departure from t he protocol for an individual 
subject can there be a departure without the sponsor’s pre -approval . The nature and reasons 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 74 of 79 Version 3.0  (Global ) for the protocol deviation /violations  will be recorded in the subject’s CRF, and the principal 
investigator [INVESTIGATOR_397904] . 
Protocol deviations/violations  must be reported in the final study report.  
10.[ADDRESS_691559] study data, subjects’ 
medical records, and CRFs in accordance with ICH guideline s, GCPs, and the respective 
local and national government regulations and guidelines.  
The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and records relevant to this study.  
Each center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP, and legal aspects . This will include on -site checking of the CRFs for 
comp leteness and clarity, cross -checking with source documents, and clarification of 
administrative matters.  
All CRF data will be entered into a clinical database . Following the correction of any errors, 
the clinical database will be locked.  
10.11  Retention of Data  
The study file and all source data should be retained until notification is given by [CONTACT_267436].  
If the investigator withdraws from the trial and relinquishes his/her responsibility for the 
maintenance and retention of records, he/she must  notify the sponsor in writing so that 
arrangements can be made to properly store the trial materials.  
10.12  Publication and Disclosure Policy  
All data and results and all intellectual  property rights in the data and results derived from the 
study will be the pr operty of the sponsor, who may utilize the data in various ways, such as 
for submission to government regulatory authorities or disclosure to other investigators.  
No publication or disclosure of study results will be permitted except as specified in a 
separate, written agreement between Theracos  Sub LLC and the investigator . If results of this 
study are reported in medical journals or at meetings, all subjects’ identities will remain 
confidential.  
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 75 of 79 Version 3.0  (Global ) [ADDRESS_691560]  
IDF (2015). "International Diabetes Federati on Diabetes Atlas Seventh Edition."  
Look, A. R. G., R. R. Wing, et al. (2013). "Cardiovascular effects of intensive lifestyle 
intervention in type 2 diabetes." N Engl J Med 369(2): 145 -154. 
Nauck, M. A. (2014). "Update on developments with SGLT2 inhibitors  in the management 
of type 2 diabetes." Drug Design, Development and Therapy 8: 1335 -1380.  
 
Santer, R., M. Kinner, et al. (2003). "Molecular analysis of the SGLT2 gene in patients with 
renal glucosuria." J Am Soc Nephrol 14(11): 2873 -2882.  
 
Scheen, A. J. a nd L. F. Van Gaal (2014). "Combating the dual burden: therapeutic targeting 
of common pathways in obesity and type 2 diabetes." Lancet Diabetes Endocrinol 2(11): 
911-922. 
 
Schwartz, S., A. N. Fabricatore, et al. (2012). "Weight reduction in diabetes." Adv Exp Med 
Biol 771: 438 -458. 
 
Seufert, J. (2015). "SGLT2 inhibitors - an insulin -independent therapeutic approach for 
treatment of type 2 diabetes: focus on canagliflozin." Diabetes Metab Syndr Obes 8: 543 -
554. 
 
Van den Heuvel, L. P., K. Assink, et al. (2002 ). "Autosomal recessive renal glucosuria 
attributable to a mutation in the sodium glucose cotransporter (SGLT2)." Hum Genet 111(6): 
544-547. 
 
Zhang, W., A. Welihinda, et al. (2011). "EGT1442, a potent and selective SGLT2 inhibitor, 
attenuates blood glucose  and HbA(1c) levels in db/db mice and prolongs the survival of 
stroke -prone rats." Pharmacol Res 63(4): 284 -293. 
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 76 of 79 Version 3.0  (Global ) Appendix 1  Schedule of Events  
 Screening  Wash -out Run-in Efficacy Assessment  Safety Extension  Follow -
up 
Visit number  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18 
Time to Randomization Visit (wk)  -11 -8 -6 -2 -0.5 0 2 4 6 12 24 36 48 60 72 84 96 98 
Off-site phone visit    X             X   
Informed Consent  X                  
EQ-5D-3L      X     X   X   X  
Screening for I/E criteria  X X   X              
Demographics and medical history  X                  
Diet & exercise counseling 
 X  X               
Physical exam      X         X    X 
Abbreviated  physical exam  X        X  X X X  X  X  
Record h eight X                  
Record body weight  X    X    X X X X X X X  X X 
Dispense diary & glucometer   X  X               
Diary & glucometer record review    X X X X X X X X X X X X X X X X 
Start wash -out  X                 
Dispense Run -in Medication     X               
Randomization       X             
Vital signs  X   X X  X X X X X X X X X  X X 
ECG  X    X      X   X   X  
Discontinue non -metformin OHA   X                 
Dispense bexagliflozin       X    X X X X X X    
Dispense glimepi[INVESTIGATOR_14956]       X X X X X X X X X X    
Blood draw for clini cal lab test  X    X    X X X X X X X  X X 
Urine collection  X    X    X X X X X X X  X X 
AE  X X X X X X X X X X X X X X X X X 
Con Med   X X X X X X X X X X X X X X X X X 
 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 77 of 79 Version 3.0  (Global ) Appendix 2  Schedule of Clinical Laboratory Tests  
 
 Screening  Wash -out Run-in Efficacy Assessme nt Safety Extension  Follow -
up 
Visit Number  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18 
Time to Randomization Visit (weeks)  -[ADDRESS_691561] (UPT)  X    X    X X X X X X X  X X 
Bexagliflozin Tablets   Theracos Sub, LLC  
Clinical Trial Protocol : THR -1442 -C-480  27 October 2016   
   
 
Confidential  Page 79 of 79 Version 3.0  (Global ) Appendix 4  Investigator’s Signature  
[CONTACT_2759]:  A Phase 3, Randomized, Double -Blind, Active -Controlled Study to 
Evaluate the Effects of Bexagliflozin versus Glimepi[INVESTIGATOR_532483] 2 Diabetes Mellitus Who Ha ve Inadequate Glycemic 
Control by [CONTACT_532575]:  THR -1442 -C-480 
V3.0 Final Date:  [ADDRESS_691562] read the protocol described above. I agree to comply with the International Conference 
on Harmonisation (ICH) Tripartite guideline on Good Clinical Practice (GCP) and all 
applicable regulations and t o conduct the study as described in the protocol.  
I agree to ensure that Financial Disclosure Statements will be completed by [CONTACT_272293] [ADDRESS_691563] of the clinical investigation without 
the prior writte n consent  of Theracos Sub , LLC.  
 
 
Signed:    Date:    
Clinical Investigator  